

Curriculum Vitae

PART I: General Information

DATE PREPARED: December, 2009

Name: David M. Nathan, M.D.

DEMOGRAPHIC INFORMATION:

Office Addresses:	Diabetes Unit Massachusetts General Hospital Bulfinch 408 Boston, MA 02114 Tel: 617-726-2875 Fax: 617-726-6781 Page: 617-726-2066	MGH Diabetes Center 50 Staniford Street Suite 340 Boston, MA 02114 Tel: 617-724-0775 Fax: 617-724-8534
--------------------------	---	---

Email: dnathan@partners.org

Home Address: 80 Temple Street
West Newton, MA 02465
Tel: 617-332-4935

Place of Birth: New York, NY

Education:

1971 B.A. Amherst College, Amherst, MA

1975 M.D. Mt. Sinai School of Medicine, New York, NY

Postdoctoral Training:

1975-1976 Intern in Medicine, Peter Bent Brigham Hospital
1976-1977 Assistant Resident in Medicine, Peter Bent Brigham
1977-1978 Senior Resident in Medicine, Peter Bent Brigham Hospital
1977-1978 Chief Resident in Medicine, West Roxbury V.A. Hospital

Licensure and Certification:

1975 Massachusetts License Registration No. 42740
1976 Diplomate, National Board of Medical Examiners
1977 Diplomate, American Board of Internal Medicine
1981 Diplomate, Endocrinology and Metabolism, American Board
of Internal Medicine

Academic Appointments:

1975-1978 Clinical Fellow in Medicine, Harvard Medical School
1978-1980 Research Fellow in Medicine, Harvard Medical School
1980-1982 Instructor in Medicine, Harvard Medical School
1982-1987 Assistant Professor of Medicine, Harvard Medical School
1987-1999 Associate Professor of Medicine, Harvard Medical School
1999- Professor of Medicine, Harvard Medical School

Hospital or Affiliated Institution Appointments:

1978-1979 Clinical Fellow in Medicine, Massachusetts General Hospital
1980-1981 Clinical Assistant in Medicine, Massachusetts General Hospital
1981-1984 Assistant in Medicine, Massachusetts General Hospital
1984-1987 Assistant Physician, Massachusetts General Hospital
1985-1986 Acting Chief, Diabetes Unit, Massachusetts General Hospital
1988-1996 Associate Physician, Massachusetts General Hospital
1996- Physician, Massachusetts General Hospital

Major Administrative Responsibilities:

1980- Director, Diabetes Clinic, Massachusetts General Hospital
1983- Director, Diabetes Research Center, Massachusetts General Hospital
1990-2008 Director, Mallinckrodt General Clinical Research Center
2008- Director, MGH Clinical Research Center of the Harvard Catalyst (CTSC) program
2008- Institutional Representative for MGH to the Harvard Catalyst (CTSC) program

Major Committee Assignments:

1986-1988 Hospital Safety Committee, Massachusetts General Hospital
1989-1990 Scientific Advisory Committee, GCRC, Massachusetts General Hospital
1993 Clinical Research Task Force. Chairman, Clinical Physiology Research Subcommittee; Co-chairman, Clinical Trials Subcommittee
1995-2000 Committee on Research, Massachusetts General Hospital
1995- Clinical Research Council, Massachusetts General Hospital
2000- Executive Committee and Founding Member, Scholars in Clinical Science Program
2000-2004 Executive Committee on Research, Massachusetts General Hospital
2004- Diabetes Council, Partners Health
2006-2008 Executive Committee, CTSA, Harvard Medical School
Chairman, "Incubator, Research Support" Subcommittee
2008- Executive Committee on Research, Massachusetts General Hospital

Professional Societies:

1971 Sigma Xi, Amherst College Chapter
1974 Alpha Omega Alpha, Mt. Sinai School of Medicine
1975 Alpha Omega Alpha, President
1980 American Diabetes Association
1981-1986 Board of Directors, American Diabetes Association, Massachusetts Affiliate
1983 National Diabetes Advisory Board, Insulin Delivery Workgroup
1984 Special Study Section, Diabetes, NIADDK
1985-1987 American Diabetes Association, National Committee on Professional Education
1992 Special Committee on Clinical Trials, NIDDK
1994 American Society of Clinical Investigation
1995-2001 Member, Subspecialty Board Diabetes, Endocrinology, and Metabolism, American Board of Internal Medicine
1996-1997 Professional Practices Committee, American Diabetes Association
1996 Member, Juvenile Diabetes Foundation Research Task Force

1997	Co-chairman, Diabetes Therapy Subcommittee of NIH Special Task Force on Directions for Diabetes Care and Research
2001	Chair, American Diabetes Association Consensus Panel on Postprandial Glycemia
2002-	Member, Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, American Diabetes Association
2003-2004	Member, Institute of Medicine Committee on Crossing the Quality Chasm
2003-2009	Member, World Health Organization Prevention and Treatment of Diabetes Group
2005-	Chair, American Diabetes Association/European Association for the Study of Diabetes Committee on Treatment of Type 2 diabetes mellitus
2006	Chair, American Diabetes Association, Consensus Committee on IFG/IGT
2007	Chair, Planning meeting for future NIDDK clinical trials, NIDDK, NIH
2008-	Chair, Expert Committee on the Diagnosis of Diabetes, American Diabetes Association, European Association for the Study of Diabetes, International Diabetes Federation, World Health Organization
2008-	Co-chair, Individualizing therapy of type 2 diabetes, Endocrine Society-ADA program
2009-	Chair, Clinical Research/Clinical Trials section, NIDDK 10 year strategic plan

Major Research Project Responsibilities

1981-1987	Co-principal Investigator – Cognitive and Sensory Function in the Aging Diabetic, National Institute on Aging, NIH
1982-1995	Principal Investigator at Massachusetts General Hospital for <u>Diabetes Control and Complications Trial</u> , a multicenter, NIH-supported 10-year study: Steering Committee (1982-1995) Planning Committee (1985-1995) Treatment Committee (1982-1985) Clinic Monitoring Group (1983-1985) Publications and Presentations Committee (1982-1995) Chairman (1985-1995) Editor for DCCT Publications (1985-1995)
1988-	Co-investigator, diabetes investigations for <u>Framingham Heart Study</u>
1990-	Co-investigator of <u>PORT</u> study on “Variations in the Management and Outcome of Type II Diabetes”, AHCPR
1990-	Co-investigator of <u>Nurses Health Study</u> , Channing Labs, Boston, MA
1994-	Principal Investigator, <u>Epidemiology of Diabetes, Interventions and Complications Trial</u> , NIDDK, NIH
1994-	Co-Chairman, <u>Epidemiology of Diabetes, Interventions and Complications Trial</u> , Long-term Follow-up of DCCT
1994-2002	Chairman, <u>Diabetes Prevention Program</u> , NIH Multicenter Trial
1999-	Principal Investigator, <u>Look:AHEAD</u> clinical trial, NIDDK, NIH
1999-2004	Director, Clinical Research Trials for JDF-Harvard Islet Transplantation Center
2001-2002	Steering Committee, <u>Prevention and Treatment of Type 2 diabetes in children and adolescents</u> , NIDDK, NIH
2001-	Data Safety Monitoring Board, <u>ACCORD Study</u> , NHLBI, NIH
2002-	Scientific Advisory Committee, <u>CRIC Study</u> , NIDDK, NIH

2002- Scientific Advisory Committee, AASK Study. NIDDK, NIH
 2002- Principal Investigator, TODAY Study. NIDDK, NIH
 2002- Chairman, Diabetes Prevention Program Outcome Study. NIDDK, NIH
 2005 Chair, External Advisory Committee, STOPP-T2D Study. NIDDK, NIH
 2005 External Advisory Committee, BARI-2D study. NHLBI, NIH
 2005- Principal Investigator, International Study of Mean Blood Glucose and HbA1c, American Diabetes Association, IDF, and EASD

Peer Review:

Frequent reviewer for *Diabetes, Diabetes Care, Diabetologia, New England Journal of Medicine, Journal of the American Medical Association, Journal of Clinical Investigation, Journal of Clinical Endocrinology and Metabolism, Annals of Internal Medicine, Lancet*

1982-1987 Associate Editor, *Clinical Diabetes*, Journal of American Diabetes Association
 1986-1987 Contributing Editor, Type I Diabetes Textbook, ADA
 1986- Chairman, Publications Committee and Editorial Board, Diabetes Control and Complications Trial
 1988-1991 Editorial Board, *Diabetes Care*
 1991-1999 Author of "Diabetes Mellitus" and "Hypoglycemia" chapters in Scientific American Medicine series
 1991-1995 Editorial Board, *Journal of Diabetes and its Complication*
 1993-1998 Associate Editor, Yearbook of Endocrinology
 1995-1996 Editorial Board, *Diabetes*
 1996-2001 Associate Editor, *Diabetes*
 1997- Editor, Epidemiology of Diabetes, Interventions and Complications (EDIC) Study
 1997-2005 Editorial Board, *American Journal of Medicine*
 1997 Guest Editor, Diabetes and the Heart, *Lancet*, 1997 (suppl 1)
 2001- Editorial Board, *Current Diabetes Reports*
 2002-2003 Editorial Board, *Up-to-date*
 2003- Co-Editor in Chief, *Up-to-date*
 2004- Editor, Harvard Medical School Publications, *Diabetes, A Plan for Living and Healthy Eating for Diabetics*

Awards and Honors:

1970 Sigma Xi
 1971 Magna Cum Laude graduate, Amherst College
 1971 Oscar E. Schotte Award for "Excellence in Scientific Research and Best Honors Thesis"
 1974 Alpha Omega Alpha
 1975 James Felt Memorial Prize for "Best All Around Performance During Four Years of Medical School", Mt. Sinai School of Medicine
 1975 Mt. Sinai Journal of Medicine Prize
 1978 United States Veterans Administration Special Commendation for "Outstanding Performance as Chief Resident, West Roxbury V.A. Hospital"
 1981-83 Capps Scholar in Diabetes, Harvard University
 1987 Outstanding Service Award, American Diabetes Association

1990-94	Senior Fellow, Walter Bradford Cannon Society, Harvard Medical School
1994-	American Society of Clinical Investigation
1994	Charles Best Award, American Diabetes Association, as part of the DCCT Research Group
1996-2004	Excellence in Teaching Award, Primary Care, Massachusetts General
1997	Saul Horowitz, Jr. Memorial Award, for outstanding contributions in investigation and teaching, Mt. Sinai School of Medicine
2001	American Association of Physicians
2002	Outstanding Physician/Clinician Award, American Diabetes Association
2003	Modan Award for Outstanding Abstract in Epidemiology, ADA
2004	Charles H. Best Award, Toronto Diabetes Association

Part II: Bibliography

Original Articles (selected from more than 320 original articles):

1. **Nathan DM.** The respiratory distress syndrome and glucocorticoid treatment: The case for enzyme induction. *Mt. Sinai J Med* 1975; 2:150-161.
2. **Nathan DM, Siegal AJ, Bunn HF.** Acute methemoglobinemia and hemolytic anemia with phenazopyridine. *Arch Int Med* 1977;137:1636-1638.
3. Thiemke WA, **Nathan DM.** Simultaneous nosocomial outbreaks caused by multiple resistant *Klebsiella pneumoniae* type 2 and 30. *J Clin Micro.* 1978;8:769-771.
4. **Nathan DM, Daniels GH, Ridgway EC.** Gastrinoma and pheochromocytoma: Is there mixed multiple endocrine adenoma syndrome? *Acta Endocrinologica* 1980; 93: 91-93.
5. **Nathan DM, Axelrod L, Flier JS, Carr D.** U-500 insulin in the treatment of antibody mediated insulin resistance. *Ann Intern Med* 1981; 94:653-656.
6. **Nathan DM, Axelrod L, Proppe KH, Wald R, Hirsch HJ, Martin DB.** Nesidioblastosis: A cause of insulin mediated hypoglycemia in an adult. *Diabetes Care* 1981; 4:383-388.
7. **Nathan DM.** Labile glycosylated hemoglobin contributes to hemoglobin A1 as measured by liquid chromatography or electrophoresis. *Clin Chem.* 1981; 27:1261-1263.
8. **Nathan DM, Avezzano ES, Palmer JL.** A rapid chemical means for removing labile glycohemoglobin. *Diabetes* 1981; 30:700-701.
9. **Nathan DM.** Successful treatment of extremely brittle, insulin-dependent diabetics with a new subcutaneous insulin pump regimen. *Diabetes Care* 1982; 5:105-110.
10. **Nathan DM, Avezzano ES, Palmer JL.** Rapid method to eliminate labile glycosylated hemoglobin from the assay for hemoglobin from the assay for hemoglobin A1. *Clin Chem.* 1982; 28:512-515.
11. **Nathan DM, Lou PL, Avruch J.** A crossover study of intensive conventional and insulin pump therapies in adult type I diabetes. *Ann Int Med.* 1982; 97:31-36.

12. **Nathan DM**, Francis TB, Palmer J. Effect of aspirin on glycosylated hemoglobin determinations. *Clin Chem.* 1983; 29:466-469.
13. **Nathan DM**. The importance of intensive supervision in determining the efficacy of insulin pump therapy. *Diabetes Care* 1983; 6:295-297.
14. Grinvalsky MA, **Nathan DM**. Diets for insulin pump and multiple daily injection therapy. *Diabetes Care* 1983; 6:241-244.
15. **Nathan DM**, Dunn BS, Francis TB. Two commercial methods evaluated for eliminating the labile fraction from the assay for glycated hemoglobin (glycohemoglobin). *Clin Chem.* 1984; 30:109-110.
16. **Nathan DM**, Singer DE, Hurxthal K, Goodson JD. The clinical information value of the glycosylated hemoglobin assay. *N Engl J Med* 1984; 310:341-346.
17. **Nathan DM**, Godine JE, Gauthier-Kelley C, Kawahara D, Grinvalsky M. Ice cream in the diet of insulin-dependent diabetic patients. *JAMA* 1984; 251:2825-2827.
18. **Nathan DM**, Raskin P. Convenient automated method for liquid chromatographic measurement of glycated hemoglobin. *Clin Chem* 1984;30:813-814.
19. Perlmutter LC, Hakami MK, Hodgson-Harrington C, Ginsberg J, Katz J, Singer DE, **Nathan DM**. Decreased cognitive function in aging non-insulin-dependent diabetics. *Am J Med.* 1984; 77:1043-1048.
20. Barbieri RL, Cooper DS, Daniels RH, **Nathan DM**, Klibanski A, Ridgway EC. Prolactin response to thyrotropin releasing hormone (TRH) in patients with hypothalamic-pituitary disease. *Fertility and Sterility* 1985; 43:66-73.
21. **Nathan DM**, Madnek SF, Delahanty L. Programming pre-exercise snacks to prevent post-exercise hypoglycemia in intensively treated insulin-dependent diabetes. *Ann Int Med.* 1985; 102:483-486.
22. Johnson RG, Godine JE, Hurxthal K, **Nathan DM**. The preparation of an acceptable placebo for NPH insulin. *Diabetes Care* 1985; 8:601-602.
23. Blackshear PJ, Shulman GI, Roussel AM, **Nathan DM**, et al. Metabolic response to three years of continuous, basal rate intravenous insulin infusion in type II diabetic patients. *J Clin Endo Metab.* 1985; 61:753-760.
24. Godine JE, Hurxthal K, **Nathan DM**. Bedside capillary glucose measurement by staff nurses in a general hospital. *Am J Med.* 1986; 80:803-806.
25. The Diabetes Control and Complications Trial (DCCT): Design and Methodologic Considerations - The DCCT Research Group. *Diabetes* 1986; 35:530-545.
26. **Nathan DM**. New methods for monitoring insulin-dependent diabetes: Clinical

- application and results. *J Kentucky Med Assoc.* 1986; 84:108-112.
27. **Nathan DM**, Singer DE, Godine JE, Harrington CH, Perlmutter LC. Retinopathy in older type II diabetics: Association with glucose control. *Diabetes* 1986; 35:797-801.
 28. Trifiro M, **Nathan DM**. Purification of rat hepatic glucokinase. *Prep Biochem.* 1986; 1986; 16(2):155-173.
 29. Goodson JD, Singer DE, Hurxthal K, **Nathan DM**. The limited clinical value of home urine testing in diabetic patients. *J Gen Int Med.* 1986; 1:243-247.
 30. **Nathan DM**, Singer DE, Godine JE, Perlmutter LC. Non-insulin-dependent diabetes in the elderly: Complications and risk factors. *Am J Med.* 1986;81:837-842.
 31. The Diabetes Control and Complications Trial (DCCT): Results of the feasibility study (phase II). The DCCT Research Group. *Diabetes* 1986;10:1-19.
 32. Perlmutter LC, Tun PA, Sizer N, **Nathan DM**. Age and diabetes-related changes in verbal fluency. *Exp Aging Research* 1987; 13:9-14.
 33. **Nathan DM**, Rosenbaum C, Protasowicki VD. Single void urine samples can be used to estimate quantitative microalbuminuria. *Diabetes Care* 1987; 10:414-418.
 34. **Nathan DM**. The glycemic index: Meat and potatoes or just gravy? *Diabetes Care* 1987; 10:524-525.
 35. Tun PA, Perlmutter LC, Russo P, **Nathan DM**. Memory self-assessment and performed in aged diabetics and non-diabetics. *Exp Aging Research* 1987; 13:151-157.
 36. Goldstein DE, Soeldner S, Cleary PA, **Nathan DM**. Feasibility of centralized measurements of glycated hemoglobin in the Diabetes Control and Complications Trial (DCCT): A multicenter trial. *Clin Chem.*1987; 33:2267-71.
 37. Geringer ES, Perlmutter LC, Stern TA, **Nathan DM**. Depression and diabetic neuropathy: A complex relationship. *J Ger Psych & Neuro.* 1988; 1:11-15.
 38. Greene D, Brown MJ, Pfeifer M, Cleary PA, Gilbert PR, Neilsen VK, Rand DL, **Nathan DM**. Factors in the development of diabetic neuropathy: Baseline analysis of neuropathy in the feasibility phase of the Diabetes Control and Complications Trial (DCCT). *Diabetes* 1988; 37:476-481.
 39. **Nathan DM**, Roussell A, Godine JE. Glyburide or insulin for metabolic control in non-insulin-dependent diabetes mellitus: A randomized double-blind study. *Ann Int Med.* 1988; 334-340.
 40. Cosimi AB, Auchincloss H, Delmonico FL, Fang L, **Nathan DM**, Tolkoff-Rubin N, Rubin N, Russell PS. Combined pancreatic and renal transplantation in diabetics. *Arch Surg.* 1988; 123:621-625.

41. Perlmutter LC, **Nathan DM**, Goldfinger SH, Russo PA, Yates J, Larkin M. Triglyceride levels affect cognitive function in non-insulin-dependent diabetes mellitus. *J Diab Complications* 1988; 2:210-213.
42. **Nathan DM**. The modern management of insulin-dependent diabetes mellitus. *Med Clin NA*. 1988; 72:1365-1378.
43. Singer DE, Coley CM, Samet JM, **Nathan DM**. Screening for diabetes mellitus. *Ann Int Med* 1988; 109:639-649.
44. Singer DE, Samet JM, Coley CM, **Nathan DM**. Tests of glycemia in diabetes mellitus. *Ann Int Med* 1989; 110:125-137.
45. Singer DE, Moulton AW, **Nathan DM**. Diabetic myocardial infarction: Interaction with other pre-infarction risk factors. *Diabetes* 1989; 38:350-357.
46. Dunbar J, Cleary PA, Siebert C, Baker L, Brink S, **Nathan DM** for the DCCT Research Group. Implementation of a multicomponent process to obtain informed consent in the Diabetes Control and Complications Trial. *Controlled Clinical Trials* 1989; 10:83-96.
47. Blackshear PJ, Roussel AM, Cohen AM, **Nathan DM**. Basal rate intravenous insulin infusion compared to conventional insulin treatment in patients with type II diabetes. *Diabetes Care* 1989; 12:455-463.
48. Tun PA, **Nathan DM**, Perlmutter LC. Cognitive and affective disorders in elderly diabetics *Clin Geriatr Med* 1990;6:731-46.
49. **Nathan DM**, Fogel HA, Godine JE, Lou PL, D'Amico DJ, Regan CDJ, Topping TM. The role of the internist in evaluating diabetic retinopathy. *Diabetes Care* 1991; 14:26-33.
50. **Nathan DM**, Fogel HA, Norman D, Russell PS, Tolkoff-Rubin N, Delmonico FL, Auchincloss H, Camuso J, Cosimi AB. Long-term metabolic and quality of life results with pancreatic/renal transplantation in IDDM. *Transplantation* 1991; 52:85-91.
51. **Nathan DM**, Schreiber E, Fogel HA, Mojsos S, Habener JF. Preliminary studies of insulinotropic action of glucagon-like peptide- I (7-37) in diabetic and non-diabetic human subjects. *Diabetes Care* 1992; 15:270-276.
52. Singer DE, **Nathan DM**, Fogel HA, Schachat AP. Screening for diabetic retinopathy. *Ann Int Med*. 1992; 116:660-671.
53. Singer DE, Schachat AP, **Nathan DM**, Patz A, et al. Screening guidelines for diabetic retinopathy. *Ann Int Med* 1992; 116:684-685.
54. Singer DE, **Nathan DM**, Anderson KM, Wilson PWF, Evans JC. The association of hemoglobin A1C with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. *Diabetes* 1992; 41:202-208.
55. Dunn FL, Schrott HG, Oexmann MJ, Castle G, Cleary PA, Steffes MW, **Nathan DM** for

the DCCT Research Group. Lipid and lipoprotein levels in patients with insulin-dependent diabetes mellitus: The Diabetes Control and Complications Trial (DCCT) experience. *Diabetes Care* 1992; 15:885-894.

56. Selam JL, Micossi P, Dunn FL, **Nathan DM**. Clinical trial of a programmable implantable pump for type I diabetes. *Diabetes Care* 1992; 15:877-885.
57. **Nathan DM**. The rationale for glucose control in diabetes mellitus. *Endocrinol. & Metab. North America* 1992; 21:221-235.
58. Manson JE, Rimm EB, Colditz GA, Willett WC, **Nathan DM**, Rosner B, Henekens CH, Speizer FE, Stampfer MJ. A prospective study of post-menopausal estrogen therapy and subsequent incidence of NIDDM. *Ann Epidemiol.* 1992; 2:665-673.
59. Manson JE, **Nathan DM**, Krolewski AS, Stampfer MJ, Willett WC. A prospective study of exercise and incidence of diabetes among U.S. male physicians. *JAMA* 1992; 268:63-67.
60. Lewandrowski K, Cheek R, **Nathan DM**, Godine JE, Hurxthal K, et al. Implementation of capillary blood glucose monitoring in a teaching hospital and determination of program requirements to maintain quality testing. *Am J Med* 1992; 93:419-426.
61. Cohen RM, **Nathan DM**, Clements RS. Hyperproinsulinemia in type II diabetes. *Diabetes Care* 1992; 15:723-24.
62. Molitch ME, Steffes MW, Cleary PA, **Nathan DM**. Baseline analyses of renal function in the Diabetes Control and Complications Trial. *Kidney International* 1993; 43:668-674.
63. **Nathan DM**. Long-term complications of diabetes mellitus. *N Engl J Med* 1993;328:676-685.
64. Fu Y, **Nathan DM**, Li F, Li X, Faustman DL. Defective MHC Class I expression on lymphoid cells in autoimmunity. *J Clin Invest* 1993; 91:2301-2307.
65. **Nathan DM**, Crofford OB, Genuth S, Lachin J, Rand L, Davis M, Siebert C, Cleary PA for the DCCT Research Group. The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus: The Diabetes Control and Complications Trial. *N Engl J Med* 1993;329:978-986.
66. Habener JF, McManus K, **Nathan DM**. Insulinotropic actions of glucagon-like peptide 1-(7-37) in diabetic and non-diabetic subjects. *Digestion* 1993;54:376-78.
67. Greenfield S, Kaplan SH, Silliman R, Sullivan L, Manning W, D'Agostino R, Singer DE, **Nathan DM**. The uses of outcomes research for medical effectiveness, quality of care and reimbursement in type II diabetes. *Diabetes Care* 1994; 17(S1):32-39.
68. Lewandrowski E, Laposata M, Eschenbach K, Camosa C, **Nathan DM**, Godine JE, Hurxthal K, Goff J. Utilization and cost analysis of bedside capillary glucose testing in a large teaching hospital: Implications for the management of point-of-care testing. *Am J*

Med 1994; 97:222-230.

69. **Nathan DM.** Prevention of long-term complications of non-insulin-dependent diabetes mellitus. *J Clin Invest Med* 1995; 18:332-339.
70. **Nathan DM,** Siebert C, Genuth S. DCCT: Design, outcome and implications. *IDF Bulletin* 1994; 39(S1):5-10.
71. Weir GC, **Nathan DM,** Singer DE. American Diabetes Association technical review on standards of care for diabetes. *Diabetes Care* 1994; 17:1514-1522.
72. **Nathan DM.** Inferences and implications: Do the DCCT results apply in NIDDM? *Diabetes Care* 1995; 18:251-257.
73. **Nathan DM.** Was it intensive therapy or glycemic control that worked in the DCCT? *Clinical Diabetes* 1995; 13:5-6.
74. Goldstein DE, Little RR, Lorenz RA, Malone JI, **Nathan DM,** Peterson CM. Technical review on tests of metabolic status to monitor diabetes mellitus. *Diabetes Care* 1995; 18:896-909.
75. **Nathan DM.** The pathophysiology of diabetic complications: how much does the glucose hypothesis explain? *Ann Int Med* 1996; 124:86-90.
76. **Nathan DM,** McKittrick C, Larkin M, Schaffran R, Singer DE. Glycemic control in diabetes mellitus: have changes in therapy made a difference? *Am J Med* 1996; 100:157-63.
77. Meigs JB, **Nathan DM,** Cupples LA, Wilson PWF, Singer DE. Tracking of glycosylated hemoglobin in the original cohort of the Framingham Heart Study. *J Clin Epidemiol* 1996; 49:411-17.
78. **Nathan DM,** Dunn FL, Bruch J, McKittrick C, Larkin M, Haggan C, Lavin-Tompkins J, Norman D, Rogers D, Simon D. Post-prandial insulin profiles with implantable pump therapy may explain decreased frequency of severe hypoglycemia, compared with subcutaneous intensive regimens, in IDDM. *Am J Med* 1996; 100:412-17.
79. Chiasson JL, Josse RG, Leiter LA, Mihic M, **Nathan DM,** Palmason C, Cohen RM, Wolever TM. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. *Diabetes Care* 1996; 19:1190-93.
80. Lachin, J, Genuth S, **Nathan DM** for the DCCT Research Group. The absence of a glycemic threshold for the development of long-term complications. *Diabetes* 1996; 45:1289-1298.
81. Dunn FL, **Nathan DM,** Scavini M, Selam J-L. Long-term therapy of IDDM with an implantable insulin pump. *Diabetes Care* 1997;20:59-63.
82. Meigs JB, Singer DE, Sullivan LS, Dukes KA, D'Agostino RB, **Nathan DM,** et.al. Metabolic control and prevalent cardiovascular disease in NIDDM: The NIDDM Patient Outcome Research Team. *Am J Med* 1997; 102:38-47.
83. Grinspoon S, Askari H, Landt M, **Nathan DM,** et al. Effects of fasting and glucose

- infusion on basal and overnight leptin concentrations in normal-weight women. *Am J Clin Nutr* 1997; 66:1352-6.
84. Meigs JB, D'Agostino RB, Wilson PWF, Cupples LA, **Nathan DM**, Singer DE. Risk variable clustering in the insulin resistance syndrome: the Framingham Offspring Study. *Diabetes* 1997; 46: 1594-1600.
 85. **Nathan DM**, Meigs J, Singer DE. The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet it is ... or is it? *Lancet* 1997; 350 (suppl 1): 4-9.
 86. Meigs JB, **Nathan DM**, Wilson PWF, Cupples LA, Singer DE. Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance. The Framingham Offspring Study. *Ann Int Med* 1998; 128:524-33.
 87. **Nathan DM**. UKPDS- Some answers, more controversy. *Lancet* 1998; 352:832-33.
 88. Genuth S, Eastman R, Kahn R, Klein R, Lachin J, Lebowitz H, **Nathan DM**, Vinicor F. Implications of the United Kingdom Diabetes Prospective Study. *Diabetes Care* 1999; 22(S1): S27-31.
 89. Cohen RA, Hennekens CH, Christen WG, Krolewski A, **Nathan DM**, Petersen MJ, KaMotte F, Manson JE. Determinants of retinopathy progression in Type 1 diabetes mellitus. *Am J Med* 1999;107:45-51.
 90. Cagliero E, Levina E, **Nathan DM**. Immediate feedback of HbA1c levels improves glycemic control in Type 1 and insulin-treated Type 2 diabetic patients. *Diabetes Care* 1999;22:1785-89.
 91. **Nathan DM**. Treating Type 2 diabetes with respect. *Ann Int Med* 1999;130:440-441.
 92. Meigs JB, Mittleman MA, **Nathan DM**, Tofler GH, Singer DE, Murphy-Sheehy PM, Lipinska I, D'Agostino RB, Wilson PWF. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. *JAMA* 2000; 283: 221-28.
 93. Lachin JM, Genuth S, Cleary P, Davis MD, **Nathan DM** for the EDIC Research Group. Retinopathy and nephropathy in patients with Type 1 diabetes four years after a trial of intensive therapy. *N Engl J Med* 2000; 342:381-9.
 94. Meigs JB, **Nathan DM**, Ordovas JM, Schaefer EJ, Cupples LA, Singer DE, Wilson PWF. Apolipoprotein E isoform polymorphisms are not associated with insulin resistance. *Diabetes Care* 2000;23: 669-74.
 95. Manson JE, Ajani UA, Liu S, **Nathan DM**, Hennekens CH. A prospective study of cigarette smoking and incidence of diabetes mellitus among U.S. male physicians. *Am J Med* 2000; 109:538-42.
 96. Hu FB, Stampfer MJ, Solomon CG, Liu S, Willett WC, Speizer FE, **Nathan DM**, Manson JE. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. *Arch Int Med* 2001; 161:1717-23.
 97. Meigs JB, Jacques PF, Selhub J, Singer DE, **Nathan DM**, et al. Fasting plasma homocysteine levels in the insulin resistance syndrome. *Diabetes Care* 2001; 24:1403-

1410.

98. Delahanty LM, Sonnenberg LM, Hayden D, **Nathan DM**. Clinical and cost outcomes of medical nutrition therapy for hypercholesterolemia: a controlled clinical trial. *JADA* 2001;101:1012-23.
99. Meigs JB, Haffner SM, **Nathan DM**, D'Agostino RB, Wilson PWF. Sample exchange to compare insulin measurements between the San Antonio Heart Study and Framingham Offspring Study. *J Clin Epidemiol* 2001; 54:1031-36.
100. Lopes de Faria JM, Katsumi O, Cagliero E, **Nathan DM**, Hirose T. Neurovisual abnormalities precede retinopathy in patients with long-term Type 1 diabetes. Graefe's *Arch Clin Exp Ophthalmol* 2001; 239: 643-48.
101. Knowler WC, Barrett-Connor E, Fowler S, Hamman R, Lachin J, Walker E, **Nathan DM** for the DPP Research Group. Reduction in incidence of Type 2 diabetes with life-style intervention or metformin. *N Engl J Med* 2002; 346:393-403.
102. Meigs JB, D'Agostino RB, **Nathan DM**, Rifal N, Wilson PWF. Longitudinal association of glycemia and microalbuminuria. *Diabetes Care* 2002; 25:977-83.
103. Grant RW, Cagliero E, Murphy-Sheehy P, Singer DE, **Nathan DM**, Meigs JB. Comparison of hyperglycemia, hypertension, and hypercholesterolemia management in patients with type 2 diabetes. *Am J Med* 2002;112: 603-609.
104. Genuth S, Lachin J, Cleary, P, **Nathan DM** for the DCCT/EDIC Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. *JAMA* 2002;287:2563-2569.
105. **Nathan DM**. The impact of clinical trials on the treatment of diabetes mellitus. *JCEM* 2002;87:1929-1935.
106. Barr GR, **Nathan DM**, Meigs JB, Singer DE. Tests of glycemia for the diagnosis of type 2 diabetes mellitus. *Ann Int Med* 2002;137:263-72.
107. Cagliero E, Apruzzese W, Perlmutter GS, **Nathan DM**. Musculoskeletal disorders of the hand and shoulder in patients with diabetes mellitus. *Am J Med* 2002; 112: 487-90.
108. Meigs JB, Larson MG, D'Agostino RB, Levy D, Clouse ME, **Nathan DM**, Wilson PWF, O'Donnell CJ. Coronary artery calcification in type 2 diabetes and insulin resistance. *Diabetes Care* 2002;25:1313-19.
109. Delahanty LM, Hayden D, Ammerman A, **Nathan DM**. Medical nutrition therapy for hypercholesterolemia positively affects patient satisfaction and quality of life outcomes. *Ann Behav Med* 2002;24:269-78.
110. Delahanty LM, Meigs JB, Hayden, **Nathan DM**. Psychological and behavioral correlates of baseline BMI in the Diabetes Prevention Program (DPP). *Diabetes Care* 2002; 25: 1992-1998.

111. **Nathan DM**. Initial management of glycemia in type 2 diabetes mellitus. *N Engl J Med* 2002; 347:1342-1349.
112. Meigs JB, **Nathan DM**, D'Agostino RB, Wilson PWF. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. *Diabetes Care* 2002; 25:1845-50.
113. Goldhaber-Fiebert J, Goldhaber-Fiebert S, Tristan ML, **Nathan DM**. Randomized controlled community-based nutrition and exercise intervention improves glycemia and cardiovascular risk factors in type 2 diabetes in rural Costa Rica. *Diabetes Care* 2003; 26: 24-29.
114. Meigs JB, Cagliero E, Dubey A, Murphy-Sheehy P, Gildesgame C, Chueh H, Barry MJ, Singer DE, **Nathan DM**. A controlled trial of web-based diabetes disease management: the MGH Diabetes Primary Care Improvement Project. *Diabetes Care* 2003;26:750-57.
115. Meigs JB, Muller DC, **Nathan DM**, Blake DR, Andres R. The natural history of progression from normal glucose tolerance to type 2 diabetes in the Baltimore Longitudinal Study of Aging. *Diabetes* 2003; 52:1475-84.
116. **Nathan DM**, Lachin J, Cleary P, Orchard T, Brillon DJ, Backlund J-Y, O'Leary DH, and Genuth S for the DCCT/EDIC Research Group. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. *N Engl J Med* 2003;348:2290-9.
117. Steffes MW, Chavers BM, Molitch ME, Cleary PA, Lachin JM, Genuth S and **Nathan DM** for the DCCT/EDIC Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy. *JAMA* 2003; 290:2159-2167.
118. Meigs JB, Wilson PWF, **Nathan DM**, D'Agostino RB, Williams K, Haffner SM. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. *Diabetes* 2003;52: 2160-7.
119. **Nathan DM**. Isolated pancreas transplantation for type 1 diabetes: a doctor's dilemma. *JAMA* 2003; 290: 2861-2863.
120. Blake DR, **Nathan DM**. Acute angle closure glaucoma following rapid correction of hyperglycemia. *Diabetes Care* 2003; 26:3197-8.
121. Huang ES, Gleason S, Gaudette R, Cagliero E, Murphy-Sheehy P, **Nathan DM**, Singer DE, Meigs JB. Health care resource utilization associated with a diabetes center and a general medicine clinic. *J Gen Int Med* 2004; 19:28-35.
122. **Nathan DM**, Herman WH. Screening for Diabetes: Can we afford not to screen? *Ann Int Med* 2004; 140: 756-58.
123. Grant RW, Cagliero E, Dubey AK, Gildesgame C, Chueh HC, Barry MJ, **Nathan DM**, Meigs JB. Clinical inertia in the management of Type 2 diabetes metabolic risk factors. *Diabetic Med* 2004 21:150-5.

124. Meigs JB, Williams K, Sullivan LM, Hunt KJ, Haffner SM, Stern MP, Villalpando CG, Perhanidis JS, **Nathan DM**, D'Agostino RB Jr, D'Agostino RB Sr, Wilson PWF. Using metabolic syndrome traits for efficient detection of impaired glucose tolerance. *Diabetes Care* 2004; 27: 1417-26.
125. Blake DR, Meigs JB, Muller DC, Najjar SS, Andres RA, **Nathan DM**. Impaired glucose tolerance, but not fasting glucose, is associated with increased levels of coronary heart risk factors: results from the Baltimore Longitudinal Study on Aging. *Diabetes* 2004; 53: 2095.
126. Grant RW, Cagliero E, Sullivan CM, Dubey AK, Estey GA, Weil EM, Gesmundo J, **Nathan DM**, et al. A controlled trial of population management. Diabetes mellitus: Putting Evidence into Practice (DM-PEP). *Diabetes Care* 2004; 27:2299-2305.
127. Miljanovic B, Glynn RJ, **Nathan DM**, Manson JE, Schaumberg DA. A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes. *Diabetes* 2004; 53: 2883-2892.
128. Delahanty L, **Nathan DM**. Research navigating the course of clinical practice in diabetes. *J Am Diet Assoc* 2004; 104:1846-53.
129. Libby P, **Nathan DM**, Abraham K, Brunzell JD, Fradkin J, Haffner SM, Hsueh W, Rewers M, Roberts T, Savage P, Skarlatos S, Wassef M, Rabadan-Diehl C. Report of the National Heart, Lung and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 diabetes mellitus. *Circulation* 2005; 111:3489-93.
130. Wexler DJ, Grant RW, Meigs JB, **Nathan DM**, Cagliero E. Sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes. *Diabetes Care* 2005; 28: 514-20.
131. Schaumberg DA, Glynn RJ, Jenkins AJ, Lyons TJ, Rifai N, Manson JE, Ridker PM, **Nathan DM**. Effect of intensive glycemic control on levels of markers of inflammation in Type 1 diabetes mellitus in the Diabetes Control and Complications Trial. *Circulation* 2005;111:2446-53.
132. **Nathan DM**, Cleary PA, Backlund J-YC, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B. Intensive diabetes treatment and cardiovascular disease in type 1 diabetes mellitus. *N Engl J Med* 2005; 353:2643-2653.
133. Smith MR, Lee H, **Nathan DM**. Insulin sensitivity during combined androgen blockade for prostate cancer. *J Clin Endocrinol Metab* 2006; 91: 1305-8.
134. Meigs JB, O'Donnell CJ, Tofler GH, Benjamin EJ, Fox CS, Lipinska I, **Nathan DM**, Sullivan LM, D'Agostino RB, Wilson PW. Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes in the Framingham Offspring Study. *Diabetes* 2006;55:530-7.
135. Delahanty LM, Conroy MB, **Nathan DM**. Psychological predictors of physical activity in the Diabetes Prevention Trial. *J Am Diet Assoc* 2006; 106:698-705.

136. Meigs JB, Wilson PW, Fox CS, Vasan RS, **Nathan DM**, Sullivan L, D'Agostino RB. Body mass index, metabolic syndrome and risk of type 2 diabetes or cardiovascular disease. *J Clin Endocrinol Metab* 2006; 91:2906-2912.
137. Florez JC, Jablonski KA, Bayley N, Pollin TI, deBakker PIW, Shuldiner AR, Knowler WC, **Nathan DM**, Altshuler D. Common genetic variants in the TCF7L2 gene influence progression to diabetes in the Diabetes Prevention Program. *N Engl J Med* 2006; 355:241-50.
138. Meigs JB, Wilson P, Fox C, Vasan R, **Nathan DM**, Sullivan L, D'Agostino Sr. RB. BMI, Metabolic Syndrome and Risk of Type 2 Diabetes or Cardiovascular Disease. *Clin Endocrinol Metab*. 2006;91:2906-12
139. **Nathan DM**, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. *Diabetologia* 2006, 49:1711-1721. (Published simultaneously in *Diabetes Care* 2006; 29: 1963-72.
140. Cleary PA, Orchard TJ, Genuth S, Wong ND, Detrano R, Backlund J-Y, Zinman B, Jacobson B, Jacobson A, Sun W, Lachin JM, **Nathan DM**. The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. *Diabetes* 2006;55: 3556-3565.
141. Heine RJ, Diamant M, Mbanya JC, **Nathan DM**. Management of hyperglycemia in type 2 diabetes: the end of recurrent failure? *BMJ* 2006;333:1200-4.
142. **Nathan DM**. Thiazolidinediones for initial treatment of type 2 diabetes? *N Engl J Med* 2006;355: 2477-80.
143. **Nathan DM**. Finding New Treatments for Diabetes—How Many, How Fast . . . How Good? *N Engl J Med* 2007; 356: 437-440.
144. Florez JC, Jablonski KA, Kahn SE, Franks PW, Dabalea D, Hamman RF, Knowler WC, **Nathan DM**, Altshuler DA. Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention Program. *Diabetes* 2007; 56: 531-36.
145. Florez JC, Jablonski KA, Sun MA, Bayley N, Kahn SE, Shamon H, Hamman RF, Knowler WC, **Nathan DM**, Altshuler DA. Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone. *J Clin Endocrinol Metab* 2007; 92:1502-09.
146. Wexler DJ, Meigs JB, Cagliero E, **Nathan DM**, Grant RW. Prevalence of hyper- and hypoglycemia among inpatients with diabetes. *Diabetes Care* 2007; 30:367-69.
147. **Nathan DM**. No time to inhale: Arguments against inhaled insulin in 2007. *Diabetes Care* 2007; 30: 442-43.

148. **Nathan DM**, Chew E, Christophi CA, Davis MD, Fowler S, Goldstein BJ, Hamman RF, Hubbard LD, Knowler WC, Molitch ME. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. *Diabet Med* 2007; 24: 137-144.
149. Lachin JM, Christophi CA, Edelstein SL, Ehrmann DA, Hamman RF, Kahn, SE, Knowler WC, **Nathan DM**. Factors associated with diabetes onset during metformin vs placebo therapy in the Diabetes Prevention Program. *Diabetes* 2007; 56:1153-9.
150. Lachin JM, Genuth S, **Nathan DM**, Rutledge BN. The hemoglobin glycation index is not an independent predictor of the risk of microvascular complications in the Diabetes Control and Complications Trial. *Diabetes* 2007; 56:1913-21.
151. **Nathan DM**, Berkwitz M. Trials that Matter: rosiglitazone, ramipril and the prevention of type 2 diabetes. *Ann Int Med* 2007; 146: 461-3.
152. Grant RW, Wexler DJ, Watson AJ, Lester WT, Cagliero E, Campbell EG, **Nathan DM**. How doctors choose medications to treat type 2 diabetes: a national survey of specialists and academic generalists. *Diabetes Care* 2007; 30:1448-53.
153. **Nathan DM**, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, Zinman B. Impaired fasting glucose and impaired glucose tolerance: implications for care. *Diabetes Care* 2007; 30:753-9.
154. Wilson PWF, Meigs JB, Sullivan L, Fox CS, **Nathan DM**, D'Agostino RB. Prediction of incident diabetes mellitus in middle-aged adults. *Arch Int Med* 2007; 167: 1068-74.
155. **Nathan DM**. Rosiglitazone and cardiotoxicity-weighing the evidence. *N Engl J Med* 2007;357: 64-66.
156. **Nathan DM**, Turgeon H, Regan S. Relationship between glycated haemoglobin levels and mean glucose levels over time. *Diabetologia* 2007; 50:2239-2244.
157. Zee RY, Germer S, Thomas A, Raji A, Rhee B, Ridker PM, Lindpaintner K, Williams GH, **Nathan DM**, Martin M. C-reactive protein gene variation and type 2 diabetes mellitus: a case control study. *Atherosclerosis* 2007; PMID:17900590.
158. Lorenzi M, Fekete GT, Cagliero E, Pitler L, Schaumberg DA, Berisha F, **Nathan DM**, McMeel JW. Retinal haemodynamics in individuals with well-controlled type 1 diabetes. *Diabetologia* 2008; 51:361-4.
159. **Nathan DM**, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Update on thiazolidinediones. *Diabetologia* 2008; 51: 8-11. (Published simultaneously in *Diabetes Care* 2008; 31: 173-5.
160. Pani L, **Nathan DM**, Grant RW. Clinical predictors of disease progression and medication initiation in untreated patients with type 2 diabetes and A1c < 7%. *Diabetes Care* 2008; 31: 386-90.

161. Lachin JM, Genuth S, **Nathan DM**, Zinman B, Rutledge BN for the DCCT/EDIC Research Group. The effect of glycemic exposure on the risk of microvascular complications in the Diabetes Control and Complications Trial—Revisited. *Diabetes* 2008; 57:995-1001.
162. Smith MR, Lee H, Fallon MA, **Nathan DM**. Adipocytokines, obesity and insulin resistance during combined androgen blockade for prostate cancer. *Urology* 2008; 71:318-22.
163. Hivert MF, Sullivan LM, Fox CS, **Nathan DM**, D'Agosino RB Sr, Wilson PW, Meigs JB. Association of adiponectin, resistin, and TNF alpha with insulin resistance. *J Clin Endo Metab* 2008; 93:3165-72.
164. Crandall JP, Knowler WC, Kahn SF, Marrero D, Florez JC, Bray GA, Haffner SM, Hoskin M, **Nathan DM**. The prevention of type 2 diabetes. *Nat Clin Pract Endocrinol Metab* 2008; 4: 382-93.
165. Delahanty LM, Nathan DM. Implications of the Diabetes Prevention Program and LookAHEAD clinical trials for lifestyle interventions. *J Am Diet Assoc.* 2008; 108:S66-72.
166. Ginde AA, Cagliero E, **Nathan DM**, Camargo CA Jr. Point-of-care glucose and hemoglobin A1c in emergency department patients without known diabetes: implications for opportunistic screening. *Acad Emerg Med* 2008; PMID: 18785943.
167. Pani L, Korenda L, Meigs JB, Driver C, Chamany S, Fox CS, Sullivan L, D'Agostino RB, **Nathan DM**. Effect of aging on A1c levels in persons without diabetes. Evidence from the Framingham Offspring Study and NHANES 2001-2004. *Diabetes Care* 2008; 31: 1991-6.
168. Ginde AA, Cagliero E, **Nathan DM**, Camargo CA Jr. Value of risk stratification to increase the predictive validity of HbA1c in screening for undiagnosed diabetes in the US population. *J Gen Intern Med* 2008; 23: 1346-53.
169. **Nathan DM**, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ for the A1c Derived Average Glucose (ADAG) Study Group. Translating the A1c assay into estimated average glucose values. *Diabetes Care* 2008; 31: 1473-8.
170. Larkin ME, Capasso VA, Chen CL, Mahoney EK, Hazard B, Cagliero E, **Nathan DM**. Measuring psychological insulin resistance: barriers to insulin use. *Diabetes Educ.* 2008; 34: 511-17.
171. Wexler DJ, **Nathan DM**, Grant RW, Regan S, Van Leuvan AL, Cagliero E. Prevalence of elevated HbA1c among patients admitted to the hospital without a diagnosis of diabetes. *J Clin Endocrinol Metab* 2008;93:4238-44. PMID: 18697862.
172. Lin J, Glynn RJ, Rifai N, Manson JE, Ridker PM, **Nathan DM**, Schaumberg DA. Inflammation and progressive nephropathy in type 1 diabetes mellitus in the Diabetes Control and Complications Trial (DCCT). *Diabetes Care* 2008; 31:2338-43. PMID: 18796620.

173. **Nathan DM**, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. *Diabetologia* 2009; 52: 17-30 PMID 18941734. (Published simultaneously in *Diabetes Care* 2009; 32: 192-203 PMID 18945920)
174. **Nathan DM**. How tight is right and how to get there. *Arch Int Med* 2008; 168:2064-6.
175. Pare G, Chasman DI, Parker AN, **Nathan DM**, Miletich JP, Zee RY, Ridker PM. Novel association of HKI with glycosylated hemoglobin in a non-diabetic population: a genome-wide evaluation of 14,618 participants in the Women's Genome Health Study. *PLoS Genet* 2008; PMID: 19096518.
176. White NH, Sun W, Cleary PA, Danis RP, David MD, Hainsworth DP, Hubbard LD, Lachin JM, **Nathan DM**. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. *Arch Ophthalmol* 2008; 126: 1707-15. PMID: 19096518.
177. Delahanty LM, **Nathan DM**, Lachin JM, Hu FB, Cleary PA, Ziegler GK, Wylie-Rosett J, Wexler D for the DCCT/EDIC Research Group. Association of diet with glycosylated hemoglobin during intensive treatment of type 1 diabetes in the Diabetes Control and Complications Trial. *Am J Clin Nutr* 2009; 89:518-24.
178. **Nathan DM**, Zinman B, Cleary PA, Backlund J-Y, Genuth S, Miller R, Orchard TJ for DCCT/EDIC Research Group. Modern Day Clinical Course of Type 1 Diabetes Mellitus after 30-years Duration. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) and Pittsburgh Epidemiology of Diabetes Complications (EDC) Experience 1983-2005. *Arch Int Med* 2009; 169:1307-16.
179. **Nathan DM**. Progress in diabetes research- what's next. *JAMA* 2009; 301: 1599-1601.
180. Ai M, Otokozawa S, Schaefer EJ, Asztalos BF, Nakajima K, Shrader P, Kathiresan S, Meigs JB, Williams G, **Nathan DM**. Glycosylated albumin and direct low density lipoprotein cholesterol levels in type 2 diabetes mellitus. *Clin Chim Acta* 2009;406:71-4. PMID 19465013.
181. **Nathan DM**, Balkau B, Bonora E, Borch-Johnsen K, Buse JB, Colagiuri S, Davidson MB, et al.. for the International Expert Committee on the Diagnosis of Diabetes. International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. *Diabetes Care* 2009; 32: 1327-1334.
182. Grant RW, Hivert M, Pandiscio JC, Florez JC, **Nathan DM**, Meigs JB. The clinical application of genetic testing in type 2 diabetes: a patient and physician survey. *Diabetologia* 2009. PMID 19727660
183. Kathiresan S, et al. Myocardial Infarction Genetics Consortium. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. *Nat Genet* 2009;41:334-41.

184. Brownstein JS, Murphy SN, Goldfine AB, Grant RW, Sordo M, Gainer V, Colecchi JA, Dubey A, **Nathan DM**, Glaser JP, Kohane IS. Rapid identification of myocardial infarction risk associated with diabetic medications using electronic medical records. *Diabetes Care*. [Epub ahead of print]PMID: 20009093
185. **Nathan DM**. The role of glycemia management in the prevention of cardiovascular disease--starting over? *Ann Intern Med*. 2009 Dec 15;151(12):888-9. PMID: 20008764
186. Cole A, **Nathan DM**, Savaria-Porter E, Copeland P, Turchin A, Brunt M, Zusman R, Barrett JA, Wexler D, Case E, McMahon GT, Mort E. An algorithm for the care of type 2 diabetes. *Crit Pathw Cardiol*. 2009 Dec;8(4):156-65.PMID: 19952550
187. Hivert MF, Sullivan LM, Shrader P, Fox CS, **Nathan DM**, D'Agostino RB Sr, Wilson PW, Benjamin EJ, Meigs JB. The association of tumor necrosis factor alpha receptor 2 and tumor necrosis factor alpha with insulin resistance and the influence of adipose tissue biomarkers in humans. *Metabolism*. 2009 Oct 19. [Epub ahead of print]
188. **Nathan DM**, Balkau B, Bonora E, Borch-Johnsen K, Buse JB, Colagiuri S, Davidson MB, et al.. for the International Expert Committee on the Diagnosis of Diabetes. International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. *Diabetes Care* 2009; 32: 1327-1334

DCCT Research Group Publications - selected from 62 original articles
(D.M. Nathan, Chairman, Editorial Board; Chairman, Publications
and Presentations Committee and Corresponding Author for all manuscripts)

189. **DCCT Research Group**. Are continuing studies of metabolic control and microvascular complications in IDDM justified?: the Diabetes Control and Complications Trial. *N Engl J Med* 1988; 318:246-250.
190. **DCCT Research Group**. Weight gain associated with intensive therapy in the Diabetes Control and Complications Trial. *Diabetes Care* 1988; 11:567-573.
191. **DCCT Research Group**. Epidemiology of severe hypoglycemia in the DCCT. *Am J Med* 1991; 990:450-459.
192. **DCCT Research Group**. A screening algorithm to identify clinically significant changes in neuropsychological function in the Diabetes Control and Complications Trial. *J Clin Exp Neuropsych* 1994; 16:303-316.
193. **DCCT Research Group**. The effect of intensive therapy on the development and progression of diabetic complications in adolescent subjects in the Diabetes Control and Complications Trial. *J of Pediatrics* 1994; 125:177-178.
194. **DCCT Research Group**. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus: The Diabetes Control and Complications Trial. *Arch Ophthalmol* 1995; 113:36-51.
195. **DCCT Research Group**. Implementation of conventional and intensive treatment in the Diabetes Control and Complications Trial. *Diabetes Care* 1995;18:361-376.

196. **DCCT Research Group.** The effect of intensive diabetes therapy on the development and progression of nephropathy in the Diabetes Control and Complications Trial. *Kid Int* 1995; 47:1703-1720.
197. **DCCT Research Group.** The effect of intensive diabetes therapy on the development and progression of neuropathy in the Diabetes Control and Complications Trial. *Ann Int Med* 1995; 122:561-568.
198. **DCCT Research Group.** Comparison of study populations in the Diabetes Control and Complications Trial and the Wisconsin Epidemiologic Study of Diabetic Retinopathy. *Arch Int Med* 1995; 155:745-754.
199. **DCCT Research Group.** The effect of intensive diabetes therapy on macrovascular disease and its risk factors in the Diabetes Control and Complications Trial. *Am J Cardiol* 1995; 75:894-903.
200. **DCCT Research Group.** Treatment-related adverse events in the Diabetes Control and Complications Trial. *Diabetes Care* 1995; 18:1415-1427.
201. **DCCT Research Group.** The association between glycemic exposure and long-term diabetic complications in the Diabetes Control and Complications Trial. *Diabetes* 1995; 44:968-983.
202. **DCCT Research Group.** Influence of intensive diabetes treatment on quality-of-life outcomes in the Diabetes Control and Complications Trial. *Diabetes Care* 1996;19:195-203.
203. **DCCT Research Group.** Effects of intensive diabetes therapy on neuropsychological function in adults in the Diabetes Control and Complications Trial. *Ann Int Med.* 1996; 24:379-88.
204. **DCCT Research Group.** Pregnancy outcomes in the Diabetes Control and Complications Trial. *Am J Obstet Gynecol.* 1996;174:1343-53.
205. **DCCT Research Group.** Lifetime benefits of intensive therapy as practiced in the Diabetes Control and Complications Trial. *JAMA* 1996; 276:1409-15.
206. **DCCT Research Group.** Hypoglycemia in the Diabetes Control and Complications Trial. *Diabetes* 1997;46:271-286.
207. **DCCT Research Group.** Effect of intensive therapy on residual B-cell function in patients with type 1 diabetes in the Diabetes Control and Complications Trial. *Ann Int Med* 1998;128:517-23.
208. **DCCT Research Group.** Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. *Arch Ophthalmol* 1998;116:874-886.
209. **DCCT Research Group.** The effect of intensive diabetes therapy and pregnancy on complications. *Diabetes Care* 2000; 23:1084-91.
210. **DCCT Research Group.** The effect of intensive diabetes therapy on body mass

and body composition in the Diabetes Control and Complications Trial. *Diabetes Care* 2001; 24:1711-21.

211. Hoedtke RD, Hampe CS, Bekris LM, Hobbs G, Bryner KD, Lernmark A, and the **DCCT Research Group**. *J of Neuroimmunol*. 2007;185:182-89.

Diabetes Prevention Program (DPP) Publications (selected from 66 publications).
(*D.M. Nathan, Study Chairman*)

212. **Diabetes Prevention Program Research Group**. The Diabetes Prevention Program: Design and methods for a clinical trial in the prevention of type 2 diabetes mellitus. *Diabetes Care* 1999, 22:623-34.
213. **Diabetes Prevention Program Research Group**. Diabetes Prevention Program. Baseline characteristics of the randomized cohort. *Diabetes Care* 2000;23: 1619-29.
214. **Diabetes Prevention Program Research Group**. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. *Hypertension* 2002; 40: 679-86.
215. **Diabetes Prevention Program Research Group**. The Diabetes Prevention Program: recruitment methods and results. *Cont Clin Trials* 2002;23: 1571-71.
216. **Diabetes Prevention Program Research Group**. The Diabetes Prevention Program (DPP): Description of the lifestyle intervention. *Diabetes Care* 2002;25:2165-71.
217. **Diabetes Prevention Program Research Group**. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. *Diabetes Care* 2003; 26:36-47.
218. **Diabetes Prevention Program Research Group**. Effect of withdrawal from Metformin on the development of diabetes in the Diabetes Prevention Program. *Diabetes Care* 2003;26:977-980.
219. **Diabetes Prevention Program Research Group**. Within-trial cost effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. *Diabetes Care* 2003; 26: 2518-2523.
220. Molitch ME, Fujimoto W, Hamman RF, Knowler WC for the **Diabetes Prevention Program Research Group**. The Diabetes Prevention Program and its global implications. *J Am Soc Nephrol* 2003; 14: S103-S107.
221. **DPP Research Group**. Achieving weight loss and activity goals among Diabetes Prevention Program lifestyle participants. *Obes Res* 2004;12: 1426-34.
222. **DPP Research Group**. Dietary intake in the Diabetes Prevention Program cohort: Baseline and 1- year post-randomization. *Ann Epidemiol* 2004; 14:763-72.
223. **DPP Research Group**. Strategies to identify adults at high risk for type 2 diabetes. *Diabetes Care* 2005; 28: 138-44.
224. Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, Hamman RF,

- Ackermann RT, Engelgau MM, Ratner, **DPP Research Group**. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. *Ann Int Med* 2005;142:323-32.
225. **DPP Research Group**. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors. *Diabetes Care* 2005; 28: 888-894.
226. **DPP Research Group**. Metformin and intensive lifestyle intervention on the prevention of the metabolic syndrome. *Ann Int Med* 2005; 142:611-619.
227. **DPP Research Group**. Depression symptoms and antidepressant medicine use in Diabetes Prevention Program participants. *Diabetes Care* 2005; 2005; 28:830-7.
228. **DPP Research Group**. The effect of intensive life style on inflammation and coagulation in Diabetes Prevention Program participants with impaired glucose tolerance. *Diabetes* 2005; 54: 1566-1572.
229. **DPP Research Group**. Prevention of type 2 diabetes with troglitazone. *Diabetes* 2005; 54: 1150-1156.
230. **DPP Research Group**. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the Diabetes Prevention Program. *Diabetes* 2005;54: 2404-2414.
231. **DPP Research Group**. Lipid, lipoproteins, c-reactive protein, and hemostatic factors at baseline in the Diabetes Prevention Program. *Diabetes Care* 2005; 28:2472-2479.
232. Brown JS, Wing R, Barrett-Connor E, Nyberg LM, Kusek JW, Orchard TJ, Na Y, Vittinghoff E, Kanaya AM, **DPP Research Group**. Lifestyle intervention is associated with lower prevalence of urinary incontinence in the Diabetes Prevention Program. *Diabetes Care* 2006; 29: 385-90.
233. Carthenon MR, Prineas RJ, Temprosa M, Zhang ZM, Uwaifo G, Molitch ME, **DPP Research Group**. The association among autonomic nervous system function, incident diabetes, and intervention arm in the Diabetes Prevention Program. *Diabetes Care* 2006; 29:914-19.
234. Kriska AM, Edelstein SL, Hamman RF, Otto A, Bray GA, Mayer-Davis EJ, Wing RR, Horton ES, Haffner SM, Regensteiner JG, **DPP Research Group**. Physical activity in individuals at risk for diabetes: Diabetes Prevention Program. *Med Sci Sports Exerc.* 2006; 38: 826-32.
235. **DPP Research Group**. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. *J Gerontol* 2006; 61:1075-81.
236. Florez JC, Jablonski KA, McAteer J, Sandhu MS, Wareham NJ, Barroso I, Franks PW, Altshuler D, Knowler WC for the **Diabetes Prevention Program**. Testing of diabetes-associated WFS1 polymorphisms in the Diabetes Prevention Program. *Diabetologia.* 2007 Dec 4; 18.

237. **The Diabetes Prevention Program Research Group.** Body size and shape changes and the risk of diabetes in the Diabetes Prevention Program(DPP). *Diabetes*.2007;56:1680-5.
238. Herman WH, Ma Y, Uwaifo G, Haffner S, Kahn SE, Horton ES, Lachin JM, Montez MG, Brenneman T, Barrett-Connor E for the **Diabetes Prevention Program Research Group.** Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. *Diabetes Care*. 2007; 30(10):2453-7.
239. Moore AF, Jablonski KA, McAteer JB, Saxena R, Pollin TI, Franks PW, Hanson RL, Shulkdiner AR, Knowler WC, Altshuler D, Florez JC, **Diabetes Prevention Program.** Extension of type 2 diabetes genome-wide association scan results in the Diabetes Prevention Program. *Diabetes* 2008;57: 2503-10.
240. **Diabetes Prevention Program Research Group.** Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. *J Clin Endocrinol Metab* 2008; 93:4774-9. PMID: 18826999.
241. **Diabetes Prevention Program Research Group.** 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. *Lancet* 2009; 374:1677-86.
242. Crandall JP, Polsky S, Howard AA, et al. and the **DPP Research Group.** Alcohol consumption and diabetes risk in the Diabetes Prevention Program. *Am J Clin Nutr* 2009;90:595-601.
243. Perrault L, Kahn SE, Christophi CA, et al. and the **DPP Research Group.** Regression from pre-diabetes to normal glucose regulation in the Diabetes Prevention Program. *Diabetes Care* 2009; 32:1583-88.
244. Franks PW, Jablonski KA, Delahanty LM, et al. and the **Diabetes Prevention Program Research Group.** Assessing gene-treatment interactions at the FTO and INSIG2 loci on obesity-related traits. *Diabetologia* 2008;51:2214-23.
245. Moore AF, Jablonski KA, Mason CC et al. for the **DPP Research Group.** The association of ENPP1 K121Q with diabetes incidence is abolished by lifestyle modification in the Diabetes Prevention Program. *J Clin Endo Metab* 2009;94:449-53.
246. Ma Y, Temprosa M, Fowler S, et al. for the **Diabetes Prevention Program Research Group.** Evaluating the accuracy of an aneroid sphygmomanometer in a clinical trial setting. *Am J Hypertens* 2009;22:263-6.
247. Goldberg RB, Temprosa M, Haffner S et al. for the **Diabetes Prevention Program Research Group.** Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin: the Diabetes Prevention Program. *Diabetes Care* 2009;32:726-32.

Epidemiology of Diabetes Interventions and Complications (EDIC) Study.
(D.M. Nathan, Study Co-chairman and Editor and Corresponding Author for all Publications)

248. **EDIC Research Group.** Epidemiology of Diabetes Interventions and Complications(EDIC): Design and implementation of a long-term follow-up of the Diabetes Control and Complications Trial Cohort. *Diabetes Care* 1999; 22:99-111.
249. **EDIC Research Group.** Effect of intensive diabetes treatment on carotid artery wall thickness in the Epidemiology of Diabetes Interventions and Complications. *Diabetes* 1999; 48:383-90.
250. **EDIC Research Group.** Beneficial effect of intensive therapy of diabetes during Adolescence: Outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). *Journal of Pediatrics* 2001; 139:804-812.
251. Virella G, Atchley D, Koskinen S, Zheng D, Lopes-Virella MF, and the **DCCT/EDIC Research Group.** Proatherogenic and proinflammatory properties of immune complexes prepared with purified human ox-LDL antibodies and human ox-LDL. *Clin Immunol* 2002;105:81-92.
252. Virella G, Thorpe SR, Alderson NL, Stephan EM, Atchley D, Wagner F, Lopes-Virella MF and the **DCCT/EDIC Research Group.** *J of Lipid Res* 2003; 44:487-93.
253. Jenkins AJ, Lyons TJ, Otvos J, Zheng D, Lackland DT, McGee D, Garvey WT, Klein R and the **DCCT/EDIC Research Group.** NMR analysis of lipoprotein subclasses in the EDIC cohort: associations with gender and glycemia. *Diabetes Care* 2003; 26:810-818.
254. Klein RL, Hunter SJ, Jenkins AJ, Zheng D, Semler AJ, Clore J, Garvey WT and the **DCCT/EDIC Research Group.** Fibrinogen as a marker for nephropathy and peripheral vascular disease in type 1 diabetes: studies of plasma fibrinogen and fibrinogen gene polymorphism in the DCCT/EDIC cohort, *Diabetes Care* 2003; 26: 1439-48.
255. **DCCT/EDIC Research Group.** Glycated hemoglobin Measurements over nearly two decades: sustaining comparable values throughout the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications Study. *Clin Chem* 2005;51: 753-758.
256. Boright A, Patterson A, Mirea L, Bull S, Scherer S, Zinman and the **DCCT/EDIC Research Group.** Genetic variation at the ACE gene is associated with persistent microalbuminuria and severe nephropathy in type 1 diabetes. *Diabetes* 2005; 54: 1238-1244.
257. **DCCT/EDIC Research Group.** Neuropathy among the Diabetes Control and Complications Trial cohort eight years after trial completion. *Diabetes Care* 2006;29:340-4.
258. Lyons TJ, Jenkins AJ, Zheng D, Klein RL, Otvos JD, Yu Y, Lackland DT, McGee S, McHenry MB, Lopes-Virella M, Garvey WT, and the **DCCT/EDIC Research Group.** Nuclear magnetic resonance-determined lipoprotein subclass profile in the DCCT/EDIC cohort: associations with carotid intima-media thickness. *Diabet Med* 2006;23:955-966.

259. Sibley SD, deBoer IH, Steffes MW, Brunzell JD and the **DCCT/EDIC Research Group**. Intra-abdominal fat and elevated urine albumin excretion in men with type 1 diabetes mellitus. *Diabetes Care* 2007;30:1898-1900.
260. **DCCT/EDIC Research Group**. The effect of intensive diabetes treatment on resting heart rate in type 1 diabetes: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. *Diabetes Care* 2007;30:2107-12.
261. Al-Kateb H, Mirea L, Xie X, Sun L, Liu M, Chen H, Bull SB, Boright AP, Paterson AD for the **DCCT/EDIC Research Group**. Multiple variants in vascular endothelial growth factor (VEGFA) are risk factors for time to severe nephropathy in type 1 diabetes. *Diabetes* 2007; 56:2161-68.
262. **DCCT/EDIC Research Group**. Subclinical neuropathy among Diabetes Control and Complications Trial participants without diagnosable neuropathy at trial completion. Possible predictors of incident neuropathy? *Diabetes Care* 2007;30:2613-18.
263. **DCCT/EDIC Research Group**. Intensive treatment of diabetes is associated with a reduced rate of peripheral arterial calcification in Diabetes Control and Complications Trial. *Diabetes Care* 2007;30:2646-48.
264. Al-Kateb H, Boright AP, Mirea L, Xie X, et al. and the **DCCT/DIC Research Group**. Multiple SOD1/SFRS15 variants are associated with the development and progression of diabetic nephropathy. *Diabetes* 2008;57: 218-28.
265. deBoer IH, Kestenbaum B, Rue Ts, et al. for the **DCCT/EDIC Study Research Group**. Insulin therapy, hyperglycemia, and hypertension in type 1 diabetes mellitus. *Arch Int Med* 2008;168:1867-73.
266. **DCCT/EDIC Research Group**. Effect of glycemic exposure on the risk of microvascular complications in the Diabetes Control and Complications Trial. *Diabetes* 2008; 57:995-2001.
267. **DCCT/EDIC Research Group**. The impact of diabetes and its treatment on cognitive function among adolescents who participated in the DCCT. *Diabetes Care* 2008; 31:1933-8.
268. Penson DF, Wessells H, Cleary P, Rutledge BN and the **DCCT/EDIC Research Group**. Sexual dysfunction and symptom impact in men with long-standing type 1 diabetes in the DCCT/EDIC cohort. *J Sex Med* 2009; 6:1969-78.
269. Sarma AV, Kanaya , Nyberg LM, et al for the **DCCT/EDIC Research Group**. Risk factors for urinary incontinence among women with type 1 diabetes: findings from the Epidemiology of Diabetes Interventions and Complications Study. *Urology* 2009;73: 1203-09.
270. Pop-Busui R, Low PA, Waberski B, et al. for the **DCCT/EDIC Research Group**. Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus. *Circulation* 2009; 119:2886-93.

271. Pezzolesi MG, et al., the **DCCT/EDIC Research Group**. Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes. *Diabetes* 2009;58: 1403-10.
272. Grant SF, Qu HQ, Bradfield L, et al. **DCCT/EDIC Research Group**. Followup analysis of genome-wide association data identifies novel loci for type 1 diabetes. *Diabetes* 2009;58: 290-5.
273. **DCCT/EDIC Research Group**. Urinary tract infections in women with type 1 diabetes mellitus: survey of female participants in the Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study cohort. *J Urology* 2009;181: 1129-35.
274. **DCCT/EDIC Research Group**. Urinary incontinence among women with type 1 diabetes: how common is it? *J Urology* 2009;181: 1224-30.
275. **DCCT/EDIC Research Group**. Effect of intensive glycemic control and diabetic complications on lower urinary tract symptoms (LUTS) in men with type 1 diabetes: Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. *Diabetes Care* 2009;32: 664-70.
276. **DCCT/EDIC Research Group**. Sexual dysfunction in women with type 1 diabetes: Long-term findings from the DCCT/EDIC study cohort. *Diabetes Care* 2009;32:780-85.
277. **DCCT/EDIC Research Group**. The role of PGC1 alpha Gly482Ser polymorphism in weight gain due to intensive diabetes therapy. *PPAR Research* 2009, in press.
278. Paterson AD, Lopes-Virella MF, Waggott D, et al. and the **DCCT/EDIC Research Group**. Genome-wide association identifies the ABO blood group as a major locus associated with serum levels of soluble E-selectin. *Athero Thromb Vasc Biol.* 2009, in press.

Look:AHEAD Study (selected from 39 publications)

279. **Look:AHEAD** (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. *Controlled Clinical Trials* 2003;24:610-628.
280. **Look AHEAD Research Group**. Baseline characteristics of the randomized cohort from the Look AHEAD (Action for Health in Diabetes) study. *Diab Vasc Dis Res* 2006;3:202-15.
281. **Look AHEAD Research Group**. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes. *Diabetes Care* 2007; 30: 1374-1383.
282. **Look AHEAD Research Group**. Impact of weight management program on health-related quality of life in overweight adults with type 2 diabetes. *Arch Int Med* 2009;169:163-71.

283. Wadden TA, West DS, Neiberg RH, Wing RR, Ryan DH, Johnson KC, Foreyt JP, Hill JO, Trence DL, Vitolins MZ; **Look AHEAD Research Group**. One-year weight losses in the Look AHEAD study: factors associated with success. *Obesity* 2009;17:713-22.
284. Williamson D, Rejeski J, Lang W, Van Dorsten B, Fabricatore AN, Toledo K; LookAHEAD Research Group. Impact of weight management program on health-related quality of life in overweight adults with type 2 diabetes. *Arch Int Med* 2009;169: 163-71.

TODAY Study

285. **TODAY Study Group**. Treatment Options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes. *Ped Diabetes* 2007; 8: 74-87.

Books and Book Chapters:

1. Perlmutter LC, **Nathan DM**, Hakami MK. Effects of diabetic treatment and gender on sensory functions in the elderly. In: Handbook of Nutrition in the Aged. Watson R, Ed. CRC Press: Boca Raton, 1985.
2. **Nathan DM**. Special subcutaneous insulin infusion regimens in brittle diabetes. In: Brittle Diabetes. Pickup J, Ed. Blackwell Scientific Publications Ltd: Oxford, 1985, pp. 232-240.
3. Perlmutter LC, **Nathan DM**, Hakami MK, Chauncey HH. Effect of non-insulin-dependent diabetes mellitus on gustation and olfaction. In: Interaction of the Chemical Senses with Nutrition. Kare and Brand, Eds. Academic Press: Orlando, FL, 1986, pp. 128-142.
4. Singer DE, Samet JH, Coley CM, **Nathan DM**. Screening for diabetes mellitus. In: Preventing Disease: Beyond the Rhetoric. Goldbloom R, Lawrence RS, Eds. Springer-Verlag: New York, 1989.
5. Singer DE, Samet JH, Coley CM, **Nathan DM**. Screening for diabetes mellitus. In: U.S. Preventative Services Task Force Report: Guide to Clinical Preventative Services. 1989, pp. 64-70.
6. Perlmutter LC, Goldfinger SH, Shore AR, **Nathan DM**. In: Neuropsychological and Behavioral Aspects of Diabetes. Holmes C, Ed. Springer-Verlag: New Nork, 1990.
7. Singer DE, Samet JH, Coley CM, **Nathan DM**. Screening for diabetes mellitus. In: A Yearbook Guide to Clinical Medicine. Stein JH, Ed. Yearbook Publishers: Chicago, 1990.
8. **Nathan DM**. To screen or not to screen. In: Frontiers of Diabetes Research: Current Trends in Non-Insulin-Dependent Diabetes Mellitus. Alberti KGGM, Mazze R, Eds. Elsevier Science Publishers: Amsterdam, 1990.
9. **Nathan DM**. Insulin treatment in the elderly diabetic patient. In: Clinics in Geriatric Medicine. Froom J, Ed. W.B. Saunders: Philadelphia, 1990.

10. Singer DE, Coley CM, Samet JH, **Nathan DM**. Tests of glycemia in diabetes mellitus: their use in establishing a diagnosis and in treatment. In: Common Diagnostic Tests: Use and Interpretation, 2nd Edition. Sox HC, Ed. American College of Physicians: Philadelphia, 1990; pp. 121-147.
11. Singer DE, Samet JH, Coley CM, **Nathan DM**. Screening for diabetes mellitus. In: Common Screening Tests. Eddy DM, Ed. American College of Physicians: Philadelphia, 1991; pp. 154-178.
12. **Nathan DM**. Diabetes Mellitus in adults. In: Conn's Current Therapy. Rakel R, Ed. W.B. Saunders: Philadelphia, 1991; pp. 495-502.
13. **Nathan DM**. Monitoring diabetes mellitus. In: Therapy for Diabetes Mellitus and Related Disorders. American Diabetes Association: Alexandria VA, 1991; 2nd Edition, 1994; pp. 87-92.
14. **Nathan DM**. The relationship between metabolic control and long-term complications. In: Joslin's Diabetes Mellitus, 13th Edition. Weir GC, Kahn CR, Eds. Lea & Febiger: Philadelphia, 1992; pp. 620-30.
15. **Nathan DM**. Diabetes mellitus. In: Scientific American Medicine. Federman DD, Rubenstein E, Eds. Scientific American: New York, 1992.
16. **Nathan DM**. Hypoglycemia. In: Scientific American Medicine. Federman DD, Rubenstein E, Eds. Scientific American: New York, 1992, 1996.
17. **Nathan DM**. Detection and treatment of complications. In: Medical Management of Non-Insulin-Dependent Diabetes, 3rd Edition. Raskin P, Ed. American Diabetes Association: Alexandria VA, 1994; pp. 63-86.
18. **Nathan DM**. Insulin management of NIDDM. In: Ellenberg and Rifkin's Diabetes Mellitus, 5th Edition. Porte D, Sherwin R, Eds. Appleton & Lange: Norwalk CT, 1995.
19. **Nathan DM**. Diabetes Mellitus. In: Yearbook of Endocrinology 1994. Bagdade JD, Ed. Mosby-Yearbook, Inc.: Chicago IL, 1994; pp. 313-350.
20. **Nathan DM**. Diabetes Mellitus. In: Yearbook of Endocrinology 1995. Bagdade JD, Ed. Mosby-Yearbook, Inc.: Chicago IL, 1995; pp. 297-332.
21. **Nathan DM**. Diabetes Mellitus. In: Yearbook of Endocrinology 1996. Bagdade JD, Ed. Mosby-Yearbook, Inc.: Chicago IL, 1996; 315-357.
22. **Nathan DM**. The treatment of diabetes to prevent and delay long-term complications: The Diabetes Control and Complications Trial. In: Diabetes Mellitus: A Fundamental and Clinical Text. LeRoith D, Olefsky J, Taylor S, Eds. J.P. Lippincott-Raven: Philadelphia, 1996; 373-78.
23. **Nathan DM** with Lauerman JF. Diabetes. Time Books- Random House, New York, 1997.

24. **Nathan DM.** Monitoring diabetes mellitus. In: Therapy for Diabetes Mellitus and Related Disorders. American Diabetes Association: Alexandria VA, 1991; 3rd Edition, 1998; pp.109-117.
25. **Nathan DM.** Diabetes Mellitus. In: Yearbook of Endocrinology 1997. Bagdade JD, Ed. Mosby. Chicago IL, 1997; 289-328.
26. **Nathan DM.** Diabetes Mellitus. In: Yearbook of Endocrinology 1998. Bagdade JD, Ed. Mosby. St. Louis MO, 1998; 293-332.
27. **Nathan DM.** Management and prevention of complications in Type 1 diabetes mellitus. In: Atlas of Clinical Endocrinology, Volume II, Diabetes. Kahn CR, Ed. Current Medicine, Phil PA, 1999; 60-67.
28. **Nathan DM.** A Special Report- Diabetes. Harvard Health Letter, Harvard Medical School Health Publications, Boston, 1999; 1-46.
29. **Nathan DM.** Diabetes Mellitus. In : World Book Encyclopedia 2000. World Book Publishing. Chicago IL, 2000.
30. **Nathan DM** and Cagliero E. Diabetes Mellitus. In: Endocrinology and Metabolism, 4th ed. Felig P, Frohman LA, Eds. WB Saunders Co. Phil PA, 2001, pp 827-926.
31. **Nathan DM.** Insulin treatment of Type 2 diabetes mellitus. In: Ellenberg and Rifkins Diabetes Mellitus, 6th edition, Porte D, Sherwin R, Eds. McGraw-Hill, NY, 2003; pp 515-522.
32. **Nathan DM.** The relationship between metabolic control and long-term complications. In: Joslin's Diabetes Mellitus, 14th Edition. Weir GC, Kahn CR, Eds. Lea & Febiger: Philadelphia, 2004; in press.
33. Saunders C, Frishman R, **Nathan DM.** Diabetes- A Plan for Living. Special Health Report from Harvard Medical School. Harvard Health Publications, 2001.
34. **Nathan DM.** Management and prevention of complications in Type 1 diabetes mellitus. In: Atlas of Clinical Endocrinology, Volume II, Diabetes. 2nd ed. Skyler J, Ed. Current Medicine, Phil PA, 2002; pp 60-70.
35. **Nathan DM**, Hamman RF, Garfield S, Brenneman A, Fowler SF, Knowler WC. Preventing Type 2 Diabetes: The Diabetes Prevention Program. In: Diabetes mellitus: A Fundamental and Clinical Text, 3rd edition. LeRoith D, Olefsky J, Taylor SI, ed. Lippincott Williams & Wilkins, Phil PA, 2004, pp 1077-1084.
36. **Nathan DM.** Insulin Treatment of Type 2 Diabetes Mellitus. In: The Diabetes Mellitus Manual: A Primary Care Companion to Ellenberg and Rifkin's Diabetes Mellitus. 1st ed. Inzucchi S, ed. McGraw Hill, NY, NY, 2004, pp. 138-149.
37. Diabetes - A Plan for Living. **Nathan DM**, ed. Harvard Health Publications, Boston, MA 2004.

38. Healthy Eating for Type 2 Diabetes. **Nathan DM**, ed. Harvard Health Publications, Boston, MA 2004.
39. **Nathan DM**, Delahanty L. Beat Diabetes. McGraw Hill, NY, NY, 2005.
40. **Nathan DM**. Diabetes control and long-term complications. In: Endocrinology, 5th edition. DeGroot LJ, Jameson JL, ed. Elsevier Saunders, Philadelphia, PA, 2005, pp. 1293-1304.
41. Lachin JM, Cleary P, Crofford O, Genuth S, **Nathan DM**, Clark C, Ferris F, Siebert C. Early termination of the Diabetes Control and Complications Trial. In: Data Monitoring in Clinical Trials. DeMets DL, Furberg CD, Friedman LM, ed. Springer, NY, NY, 2006, pp. 93-108.
42. Eisenstadt S, **Nathan DM**. Everywoman's Guide to Diabetes. Harvard University Press, Cambridge, MA, 2006.

Abstracts (selected from more than 250 abstracts):

1. Thiemke WA, **Nathan DM**. Simultaneous nosocomial epidemics with resistant Klebsiella pneumoniae. *Hospital Infection Control* 1978; 5:178.
2. **Nathan DM**, Axelrod LA, Proppe KH, Martin DB. Nesidioblastosis as a cause of insulin-mediated hypoglycemia in adults. *Clin Res* 1979; 27:594A.
3. **Nathan DM**, Axelrod LA, Flier JS, Carr D. U-500 regular insulin in the treatment of antibody-mediated insulin resistance. *Clin Res* 1981; 29:417A.
4. **Nathan DM**. Successful treatment of extraordinarily brittle diabetes with a novel insulin pump protocol. *Diabetes* 1981; 30: Suppl 1:38A.
5. Domingue JM, **Nathan DM**, Shahani BT et al. Serial electrophysiologic studies in “brittle” juvenile diabetics undergoing continuous insulin infusion. *Nerve and Muscle* 1981; 1:443.
6. **Nathan DM**. A cross-over of intensive conventional and insulin pump therapies in adult type I diabetics. *Clin Res* 1981; 29:682A.
7. **Nathan DM**. Intensive supervision in the efficacy of insulin pump regimens. Toronto International Symposium on Pump Therapy, June, 1982.
8. Singer DE, **Nathan DM**, Hurxthal K, Goodson JD. The clinical information value of the glycosylated hemoglobin assay. *Clin Res* 1983; 31:237A.
9. Goodson JD, Singer DE, Hurxthal K, **Nathan DM**. The clinical value of home urine testing in the diabetic patient. *Clin Res* 1983; 31:640A.
10. **Nathan DM**, Singer DE, Perlmutter LC, Harrington C, Ginsberg J, Katz J, Hakami M. Hemoglobin A1C influences prevalences of complications in elderly type II diabetics. *Diabetes* 1983; 32:99A.
11. Perlmutter LC, Katz J, Ginsberg J, Singer DE, Harrington C, **Nathan DM**. Cognitive deficits in elderly type II diabetics. *Diabetes* 1983; 32:39A.
12. Buchwald H, Mauser SM, Blackshear PH, **Nathan DM**, Rohde TD, Wigness D, Groppoli TJ, Steffes MW. Experimental diabetes in the dog: maximized treatment for three years reduces the severity of renal lesions. *Diabetes* 1984; 33:3A.
13. Godine JE, Hurxthal K, **Nathan DM**. Capillary blood glucose monitoring in a general hospital. *Diabetes* 1984; 33:26A.
14. Katz J, Perlmutter LC, Flannery K, **Nathan DM**. Cognitive function in maturity onset diabetes. Eastern Psychological Association Proceedings and Abstracts 1985; 56:31.
15. **Nathan DM**, Wetstein L. Can ice cream be included in the diets of long-term diabetics?: a long-term cross-over trial. *Clin Res* 1985; 35:440A.
16. **Nathan DM**, Roussell AM, Godine JE, Blackshear PJ. A comparison of implantable

- infusion therapy with conventional insulin therapies in type II diabetes: a randomized controlled clinical trial. *Diabetes* 1985; 34(S1):G2A.
17. **Nathan DM**, Rosenbaum C, Protasowicki VD. Single void urine specimens can be used to estimate quantitative microalbuminuria. *Diabetes* 1986; 35(S1): 107A.
 18. Singer DE, **Nathan DM**, Godine JE, Perlmutter LC. Retinopathy in older type II diabetics: association with glucose control. *Clin Res* 1986; 34:383A.
 19. Moulton AW, Singer DE, **Nathan DM**. Diabetic risk in myocardial infarction: epidemiologic analysis of an old clinical question. *Clin Res* 1986; 34:378A.
 20. Goldstein D, Soeldner S, **Nathan DM**. Feasibility of long-term, precise measurements of glycosylated hemoglobin for the Diabetes Control and Complications Trial (DCCT). *Diabetes* 1986; 35(S1):95A.
 21. **Nathan DM**, Godine JE, Lou PL, Topping TM. The role of internists in the diagnosis of diabetic retinopathy. *Diabetes* 1987; 36(S1):49A.
 22. Godine JE, Roussell A, **Nathan DM**. Are glyburide and insulin equally efficacious in achieving normoglycemia in NIDDM: a placebo controlled trial. *Diabetes* 1987;36(S1):133A.
 23. Singer DE, **Nathan DM**, Wilson PWF, Anderson KM. Glycated hemoglobin is associated with cardiovascular disease in females of the Framingham cohort, even among non-diabetics. *Clin Res* 1988; 36:350A.
 24. Fogel HF, Godine JE, Lou PL, D'Amico D, Regan C, Topping TM, **Nathan DM**. Can diabetologists screen for diabetic retinopathy? *Diabetes* 1989; 38(S2):45A.
 25. Schreiber E, Norman D, Cosimi AB, Rubin N, **Nathan DM**. Long-term metabolic and quality of life results with simultaneous pancreas/renal transplants. *Diabetes* 1989; 38(S2): 106A.
 26. **Nathan DM**, Schrott HG, Dunn FL, Cleary PA. Are lipid and lipoprotein levels altered in IDDM?: baseline studies in 1569 subjects screened in the DCCT. *Diabetes* 1990; 39(S1):46A.
 27. **Nathan DM**, Fogel HF, Habener JH. Insulinotropic action of Glucagon-like peptide-I, 7-37 (GLP-I [7-37]) in non-diabetic and NIDDM subjects. *Diabetes* 1990; 39(S1):142A.
 28. Singer DE, **Nathan DM**, Wilson PWF, Anderson KM. Hemoglobin A1C as a risk factor for cardiovascular disease in the Framingham study. *Clin Res* 1990;38:228A.
 29. Selam J-L, Micossi P, Dunn F, **Nathan DM**, et al. Large-scale, multi-center evaluation of a programmable implantable insulin pump in type I diabetes. *Diabetes* 1991;40(S1):424A.
 30. Manson J, **Nathan DM**, Stampfer M, Willett W, Hennekens C. A prospective study of exercise and incidence of diabetes in U.S. male physicians. *Diabetes* 1992; 41(S1):128A.

31. Santiago J, **Nathan DM**, Cleary P. Comparison of IDDM populations in the DCCT and Wisconsin Epidemiological Study of diabetic complications: are the DCCT results generalizable? *Diabetes* 1994; 43(S1):27 A.
32. Chiasson JL, Josse RG, Leiter L, Mihic M, **Nathan DM**, Palmason C, Wolever T. Can we prevent the development of NIDDM? *Diabetes* 1994; 43(S1):199A.
33. Meigs JB, Singer DE, **Nathan DM**, et al. Metabolic abnormalities associated with glucose intolerance extend across the spectrum of prevalent glucose tolerance in 3297 Framingham offspring study subjects. *Diabetes* 1995; 44(S1):5A.
34. Meigs JB, Singer DE, Sullivan L, Dukes K, **Nathan DM**, et al. Glycemic control and prevalent cardiovascular disease in a large cohort with type II diabetes. *Diabetes* 1995; 44(S1):172A.
35. Meigs JB, D'Agostino RB, Cupples LA, Wilson PWF, **Nathan DM**, Singer DE. Evidence that insulin resistance does not unify metabolic cardiovascular disease risk variable clustering: the Framingham Offspring Study. *Diabetes* 1996;45(S2): 137A.
36. Meigs JB, Mittleman MA, Sutherland P, Lipinska I, Muller JE, **Nathan DM**, Wilson PWF, Singer DE. Hemostatic function and fasting insulin across the spectrum of glucose tolerance: The Framingham Offspring Study. *Diabetes* 1996;45(S2): 193A.
37. Mittleman M, Meigs JB, Waxman S, Singer DE, Sutherland P, Matheney T, Lipinski I, Stec J, Muller J, **Nathan DM**, Wilson PWF, Toffler G. Impaired glucose tolerance and hemostasis: the Framingham Offspring Study. *Circulation* 1996;93:626.
38. Meigs JB, Cupples LA, Wilson PWF, **Nathan DM**, Singer DE. Familial aggregation of glucose intolerance by direct ascertainment of parents and offspring: the Framingham Study. *Diabetes* 1997;46 (suppl 1): 20A.
39. Wilson PWF, Cupples LA, Meigs JB, Couropmitree N, Singer DE, **Nathan DM**. Genome scan for impaired glycemic status: results from the Framingham Heart Study. *Diabetes* 1997;46 (suppl 1): 76A.
40. Meigs JB, Cupples LA, Wilson PWF, **Nathan DM**, Singer DE. Excess transmission of glucose intolerance by mothers with onset of NIDDM during childbearing years: the Framingham Study. *Diabetes* 1997;46 (suppl 1): 139A.
41. Meigs J, Mittleman M, Ordovas J, Cupples L, D'Agostino R, Singer D, **Nathan DM**. Plasminogen Activator Inhibitor-1 and small dense LDL lipoprotein levels in the insulin resistance syndrome: the Framingham Offspring Study. *Am J Cardiology* in press.
42. Meigs J, Ordovas J, Cupples A, Singer DE, **Nathan DM**, Schaefer E, Wilson PWF. Insulin resistance is unrelated to apolipoprotein E polymorphism: the Framingham Offspring Study. *Am J Cardiology*, in press.
43. Cagliero E, Apruzzese W, Perlmutter G, **Nathan DM**. Periarticular syndromes associated with diabetes mellitus. *Diabetes* 1998; 47(S1): A85.

44. Lachin J, Cleary P, Molitch M, **Nathan DM**, and the DCCT Research Group. Pregnancy increases the risk of complications in the DCCT. *Diabetes* 1998; 47(S1):A50.
45. Meigs JB, Cupples LA, **Nathan DM**, Singer DE, Tofler GH, Wilson PWF. Elevated metabolic risk factors among nondiabetic offspring with parental diabetes: the Framingham Heart Study. *Diabetes* 1998; 47(S1):A154.
46. Meigs JB, Wilson PWF, D'Agostino RB, Murphy-Sheehy P, **Nathan DM**, Singer DE. Association of HbA1c with incident cardiovascular disease in elderly subjects of the Framingham Heart Study. *Diabetes* 1998; 47(S1): A154.
47. Cagliero E, Farefield WP, **Nathan DM**. Quality of care provided to Type 2 diabetic patients by endocrinologists and internists. *Diabetes* 1998; 47(S1):A189.
48. Delahanty LM, Sonnenberg LM, **Nathan DM**. Effectiveness of medical nutrition therapy in the treatment of hypercholesterolemia. *Diabetes* 1998; 47(S1): A268.
49. Lachin J, Cleary P, Davis M, **Nathan DM**, Genuth S. Progression of retinopathy in the DCCT cohort after 4 years follow-up in the EDIC study. *Diabetologia* 1998; 41 (Suppl 1):A281.
1. Orchard T, Cleary P, Genuth S, **Nathan DM**. Correlates of lower extremity arterial disease in Type 1 diabetes. *Diabetologia* 1998; 41(Suppl 1):A334.
51. Lachin JM, Genuth S, **Nathan DM**, Davis MD, Cleary P, EDIC Research Group. Prolonged effects of DCCT intensive therapy on complications after four years of EDIC followup. *Diabetes* 1999; 48(S1): A19.
52. Cagliero E, Meigs JB, Murphy-Sheehy P, Barry MJ, Singer DE, **Nathan DM**. Differences in Type 2 diabetes and care provided in endocrine vs general medicine setting. *Diabetes* 1999; 48(S1):A40.
53. Meigs JB, Jacques P, Selhub J, Murphy-Sheehy P, **Nathan DM**, Singer DE, D'Agostino R, Wilson P. Plasma homocysteine levels do not increase significantly across the spectrum of glucose tolerance: the Framingham Offspring Study. *Diabetes* 1999; 48(S1): A165.
54. Meigs JB, Jacques P, Selhub J, Murphy-Sheehy P, **Nathan DM**, Singer DE, D'Agostino R, Wilson P. Elevated plasma homocysteine levels are more prevalent among Framingham Offspring study subjects with the insulin resistance syndrome. *Diabetes* 1999; 48(S1): A165.
55. Cagliero E, Meigs JB, Murphy-Sheehy P, Barry MJ, Singer DE, **Nathan DM**. Hypoglycemic drug utilization among Type 2 diabetic patients followed by endocrinologists and internists. *Diabetes* 1999; 48:(S1): A418.
56. Goldstein DE, Little RR, Wiedmeyer H, Eckfeldt J, Myers GL, **Nathan DM**, Parker M, Reed RG, Mewssenger LJ, Steffes MW, Gunter EW, Robbins DC. The National

- glycohemoglobin standardization program (NGSP): a progress report. *Diabetes* 1999; 48(S1):LB-34.
57. Meigs JB, Cagliero E, Murphy-Sheehy P, **Nathan DM**, et al. Use of a simple claims-based algorithm to identify type 2 diabetic patients for intensive management. *J Gen Int Med* 1999; 14 (suppl 2):55.
 58. Meigs JB, Cagliero E, Murphy-Sheehy P, **Nathan DM**, et al. Cardiovascular disease prevention practices in an academic medical center for patients with type 2 diabetes. *J Gen Int Med* 1999; 14 (suppl 2):54.
 59. Lorenzi G, Backlund JY, Herman W, Songer D, **Nathan DM**, Cleary P for the DCCT/EDIC Research Group. Health insurance affects care in Type 1 diabetes: Epidemiology of Diabetes Interventions and Complications. *Diabetes* 2000; 49(S1):A221.
 60. Genuth S, Cleary P, Molitch M, **Nathan DM**, O'Leary D. Carotid artery wall thickness in the DCCT/EDIC cohort. *Diabetologia* 2000 (suppl).
 61. Little R, Goldstein DE, Wiedemeyer H, Rohlfing CL, Myers GL, Sacks DB, **Nathan DM**, et al. The National Glycohemoglobin Standardization Program (NGSP): 4 year update. *Clin Chem* 2001
 62. Little R, Goldstein DE, , Myers GL, Gunter EW, **Nathan DM**, et al. Glycohemoglobin (GHB) standardization: has it been achieved? *Diabetes* 2001; 50 (suppl 2):
 63. Meigs JB, Wilson PWF, D'Agostino RB, **Nathan DM**. Post-challenge hyperglycemia is an independent risk factor for cardiovascular disease. *Diabetes* 2001; 50 (suppl 2):A29.
 64. Meigs JB, Cagliero E, Chueh H, Dubey A, Murphy-Sheehy P, Gildesgame C, Barry MJ, Singer DE, **Nathan DM**. The MGH Diabetes Primary Care Improvement Project: A controlled trial of a web-based patient-specific decision support tool. *Diabetes* 2001; 50 (suppl 2):A 250.
 65. Delahanty LM, Hayden D, **Nathan DM**. Psychological and behavioral correlates of baseline body weight in the Diabetes Prevention Program. *Diabetes* 2001;50 (suppl 2): A390.
 66. Blake DR, Meigs JB, Muller DC, **Nathan DM**, Andres R. Cardiovascular disease risk profile among subjects progressing from normal to abnormal glucose homeostasis in the Baltimore Longitudinal Study of Aging (BLSA). *Diabetes* 2002; 51 (suppl 2): A219.
 67. Meigs JB, Blake DR, Muller DC, **Nathan DM**, Andres R. Natural history of progression from normal to abnormal glucose homeostasis in the Baltimore Longitudinal Study of Aging (BLSA). *Diabetes* 2002; 51 (suppl 2): A233.
 68. Meigs JB, Haffner SM, Williams K, **Nathan DM**, D'Agostino RB, Wilson PWF. Prevalence of metabolic syndrome by NCEP-ATP3 criteria in the San Antonio and Framingham Offspring Study. *Diabetes* 2002; 51 (suppl 2): A233.

69. Delahanty L, Meigs JB, Hayden D, **Nathan DM**. Psychological and behavioral predictors of weight outcomes in the Diabetes Prevention Program. *Diabetes* 2002; 51 (suppl 2): A447.
70. Blake D, Meigs J, Muller D, **Nathan DM**, Andres R. Physiologic changes during progression of abnormal glycemia in the Baltimore Longitudinal Study of Aging. *Diabetes* 2003; 52 (suppl 1):A 57.
71. Blake D, Muller J, Meigs J, Najjar S, **Nathan DM**, Andres R. Association between coronary heart disease (CHD) risk and impaired glucose homeostasis in the Baltimore Longitudinal Study of Aging. *Diabetes* 2003; 52 (suppl 1):A 151.
72. Meigs J, Hunt K, Stern M, **Nathan, DM**, D'Agostino R Sr, D'Agostino R Jr, Wilson P. Using metabolic syndrome traits (MetS) to aid detection of impaired glucose tolerance (IGT). *Diabetes* 2003; 52 (suppl 1):A 225.
74. Delahanty L, Meigs J, Hayden D, **Nathan DM**. Psychological and behavioral predictors of long-term weight loss in the Diabetes prevention Program (DPP). *Diabetes* 2003; 52 (suppl 1):A 411.
75. Schaumberg DA, Glynn RJ, Jenkins AJ, Lyons TJ, Rifai N, Ridker PM, Manson JE, **Nathan DM**. Effecty of intensive glycemic control on levels of markers of inflammation in the Diabetes Control and Complications Trial. *AHA Epidemiology* 2004.
76. Wexler DJ, Meigs JB, **Nathan DM**, Grant RW, Cagliero E. Gender disparities in treatment of CHD risk factors in patients with diabetes. *Diabetes* 2004; 53 (suppl 2): A295.
77. Cagliero E, Chandraker A, Dea A, Fritz SM, **Nathan DM**, Pavlakis M, Omer AD, Weir GC, Auchincloss H. Islet cell transplantation in type 1 diabetic recipients of renal allografts. *Diabetes* 2004; 53 (suppl 2): A452.
78. Cagliero E, Feke G, Pitler L, McMeel W, Menke M, **Nathan DM**, Lorenzi M. Retinal blood flow abnormalities do not precede detectable retinopathy in subjects with well-controlled type 1 diabetes. *Diabetes* 2005; 54(suppl 1):A7.
79. Meigs JB, Wilson PWF, Toffler GH, Fox GS, **Nathan DM**, D'Agostino RB, O'Donnell CJ. Markers of endothelial dysfunction predict incident type 2 diabetes. *Diabetes* 2005; 54 (suppl 1): A90.
80. Wilson PWF, Meigs JB, Sullivan L, **Nathan DM**, D'Agostino RB. Prediction rule for incident type 2 diabetes in Framingham Offspring. *Diabetes* 2005; 54 (suppl 1): A91.
81. **Nathan DM**, Turgeon H, Regan S. Translation of glycosylated hemjoglobin levels into mean blood glucose (MBG) levels, revisited. *Diabetes* 2006; 55 (suppl 1): A96.

82. Meigs JB, Fox C, Wilson P, **Nathan DM**, Vasani R, Benjamin E, Sullivan L, D'Agostino R. Changes in insulin resistance and weight over time are associated with changes in metabolic risk factor clustering. *Diabetes* 2006; 55 (suppl 1): A221.
83. Meigs JB, Fox C, **Nathan DM**, Sullivan L, D'Agostino R, Wilson P. Low adiponectin and high resistin and TNF- α levels are associated with increased insulin resistance in pre-diabetes. *Diabetes* 2006; 55 (suppl 1): A221.
84. Carter RE, Cleary PA, Lackland DT, Yim E, Gilbert GE, Lopes-Virella M, **Nathan DM**, Orchard TJ. Intensive treatment of diabetes is associated with a reduced rate of peripheral artery calcification in DCCT/EDIC. *Diabetes* 2007;56 (S1):A32.
85. **Nathan DM**, Zinman B, Cleary PA, Backlund J-Y, for the DCCT/EDIC Research Group. *Diabetes* 2007;56 (S1):A260.
86. Grant RW, Wexler DJ, Watson AJ, Lester WT, **Nathan DM**. How doctors choose medications to treat type 2 diabetes: a national survey of generalists and specialists. *Diabetes* 2007;56 (S1):A307.
87. Grant RW, Wexler DJ, Lester WT, **Nathan DM**, Meigs JB. Wide variation in the sequence of medications prescribed for glycemic control. *Diabetes* 2007;56 (S1):A315.
88. Pani LN, Grant RW, **Nathan DM**. Medication initiation among patients with type 2 diabetes and elevated A1C. *Diabetes* 2007;56 (S1):A318.
89. Larkin M, Capasso V, Chen C-L, Mahoney E, Hazard B, Cagliero E, **Nathan DM**. Measuring psychological insulin resistance: barriers to insulin use. *Diabetes* 2007;56 (S1):A504.
90. Kuenen JC, Borg R, Zheng H, Schoenfeld D, Heine RJ, **Nathan DM**. Does glucose variability influence the relationship between average glucose and HbA1c levels? *Diabetes* 2008;57 (S1):A245.
91. Pani L, Korenda L, Meigs JB, Driver C, Chamany S, Fox CS, Sullivan L, D'Agostino RB, **Nathan DM**. Effect of aging on A1C levels in persons without diabetes: evidence from the Framingham Offspring Study and NHANES 2001-2004. *Diabetes* 2008;57 (S1):A267
92. Larkin ME, Backlund JY, Cleary P, Bayless M, Schaefer B, Canady J, **Nathan DM**. Disparity in the management of CHD risk factors by sex in the DCCT/EDIC cohort. *Diabetes* 2009;58 (S1):A177.
93. Kuenen JC, Borg R, Button EA, **Nathan DM**, Zheng H, Kostense P, Heine RJ, Diamant M. 1,5 AnhydroGlucitol concentrations and measures of glucose control and glucose variability in T1DM and T2DM patients. *Diabetes* 2009;58 (S1):A233.
94. Borg R, Kuenen JC, Carstensen B, Witte DR, Nerup J, Zheng H, Heine RJ, **Nathan DM**. HbA1c and mean blood glucose show stronger association to CVD risk factors than postprandial glycemia or glucose variability. *Diabetes* 2009;58 (S1):A24.

95. Russell SJ, El-Khatib FH, Sutherlin R, **Nathan DM**, Damiano ER. A clinical feasibility trial of bi-hormonal closed-loop blood glucose control for type 1 diabetes. *Diabetes* 2009;58 (S1):A262.
96. Blumenthal KJ, Larkin ME, Winning GS, **Nathan DM**, Grant RW. Predictors of change in metabolic control from 1996 to 2006 among adults with type 2 diabetes: A longitudinal cohort study. *Diabetes* 2009;58 (S1):A269.
97. Grant RW, Hivert M-F, Pandiscio JC, Campbell EG, Florez JC, **Nathan DM**, Meigs JB. The clinical application of genetic testing for type 2 diabetes: a patient and physician survey. *Diabetes* 2009;58 (S1):A312.

Diabetes Control and Complications Trial - selected from 58 abstracts
(D.M. Nathan, Chairman, Editorial Board; Chairman, Publications and Presentations Committee)

98. **The DCCT Research Group.** Diabetes Control and Complications Trial (DCCT): Design and commencement. *Controlled Clinical Trials* 1983; 4:146.
99. **The DCCT Research Group.** Fully informed consent: the Diabetes Control and Complications Trial approach to the informed consent process. *Controlled Clinical Trials* 1984; 5:293.
100. **The DCCT Research Group.** Baseline characteristics of patients randomized during phase II of the Diabetes Control and Complications Trial (DCCT). *Diabetes* 1984; 33(S1):57.
101. **The DCCT Research Group.** Retention of informed consent information at one year: the DCCT experience. *Controlled Clinical Trials* 1985; 6:22.
102. **The DCCT Research Group.** Validity and reliability studies of the Diabetes Control and Complications Trial's quality of life assessment. *Controlled Clinical Trials* 1985; 6:22.
103. **The DCCT Research Group.** Results of feasibility phase of the Diabetes Control and Complications Trial (DCCT): glycemic control, follow up and complications of therapy. *Diabetes* 1986; 35(S1):3A.
104. **The DCCT Research Group.** Residual B-Cell function in IDDM patients in the Diabetes Control and Complications Trial (DCCT): relationship to diabetes duration, metabolic control and treatment. *Diabetes* 1986; 35(S1):15A.
105. **The DCCT Research Group.** Age and gender are factors in the development of diabetic neuropathy: baseline neurologic assessment in the Diabetes Control and Complications Trial. *Diabetes* 1986; 35(S1):12A.
106. **The DCCT Research Group.** A new multi-center clinical trial in diabetes: a view from the bottom. *Controlled Clinical Trials* 1987; 3:1389.

107. **The DCCT Research Group.** Long-term metabolic outcome and complications with intensive therapy in the Diabetes Control and Complications Trial. *Diabetes* 1989; 38(S2):81A.
108. **The DCCT Research Group.** Adherence to study protocol and predictors of success in intensive therapy over five years in the DCCT. *Diabetes* 1990; 39(S1):111A.
109. **The DCCT Research Group.** Baseline analysis of renal function in the DCCT. *Diabetes* 1990; 39(S1):70A.
110. **The DCCT Research Group.** Effect of intensive therapy on renal function during the DCCT. *Diabetes* 1994; 43(S1):147A.
111. **The DCCT Research Group.** Outcome of pregnancies in the Diabetes Control and Complications Trial. *Diabetes* 1995; 44(S1):13A.
112. **The DCCT Research Group.** Influence of intensive diabetes treatment on body weight and composition of adults in the DCCT. *Diabetes* 1995; 44(S1):29A.
113. **The DCCT Research Group.** Pregnancy increases the risk of complications in the DCCT. *Diabetes* 1998; 47(S1):A50.

Epidemiology of Diabetes Interventions and Complications (D.M. Nathan, Study Co-Chairman, Chairman Steering Committee, Editor for all publications-selected from 50 abstracts)

114. **EDIC Study Group.** Post-study access to health care has influenced glycemic control in the DCCT cohort: EDIC follow-up study. *Diabetes* 1996; 45(suppl 2):7A.
115. **EDIC Study Group.** Self-care practices and outcomes in the DCCT cohort two years post-completion: EDIC follow-up study. *Diabetes* 1996; 45(suppl 2):A124.
116. **EDIC Study Group.** The effect of intensive diabetes treatment on carotid artery wall thickness in the EDIC study. *Diabetes* 1996; 45(suppl 2):A188.
117. **EDIC Study Group.** Progression of retinopathy in the DCCT cohort after 4 years of followup in the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. *Diabetologia* 1998; 41 (Suppl 1):A281.
118. **EDIC Study Group.** Micro and macroalbuminuria prevalences in the Epidemiology of Diabetes Interventions and Complications (EDIC). *Diabetologia* 1998; 41 (Suppl 1):A285.
119. Greene D, Martin C, Feldman E for the **EDIC Study Group.** Neuropathy assessment by the Michigan neuropathy screening instrument in the Post-DCCT follow-up EDIC cohort. *Diabetologia* 1998; 41 (Suppl 1):A51.
120. **EDIC Study Group.** Measures of sub-clinical cardiovascular disease in the Epidemiology of Diabetes Interventions and Complications. *Circulation* 1998; 98(Suppl):I-516.

121. White N, Dahms W, Malone J, Tamborlane W, Goldstein D, Cleary P for the **DCCT/EDIC Study Group**. Prolonged effects of DCCT intensive therapy in adolescents on diabetes complications after four years followup in EDIC. *Diabetes* 2000; 49(S1):A47.
122. **DCCT/EDIC Study Group**. Changes in carotid artery wall thickness in the DCCT/EDIC cohort. *Diabetes* 2001; 50 (suppl 2):A74.
123. Cleary P, Orchard T, Zinman B, Wong N, Detrano R, Backlund J-Y, Genuth S for the **DCCT/EDIC Study Group**. Coronary calcification in the Diabetes Control and Complications trial/Epidemiology of Diabetes interventions and Complications (DCCT/EDIC) cohort. *Diabetes* 2003;52 (suppl 2):A152.
124. White NH, Cleary PA, Tamborlane WV, Sun W, Danis R, Lachin J, Genuth S, Zinman B, and **DCCT/EDIC Research Group**. Effect of Prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in DCCT/EDIC: Comparison of adults and adolescents. *Diabetes* 2005; 54 (suppl 1):A224.
125. Genuth S, Monnier V, Sun W, and the **DCCT/EDIC Research Group**. Glycation products in skin collagen predict future progression of retinopathy over ten years in type 1 diabetes. *Diabetes* 2005; 54 (suppl 1):A226.
126. Jacobson A, Cleary P, Waberski B, Sparks C and the **DCCT/EDIC Research Group**. Influence of intensive diabetes treatment on diabetes quality-of-life outcomes 10 years post-DCCT. *Diabetes* 2005; 54 (suppl 1):A19.
127. Wessels H, Penson D, Cleary P, Rurledge B, Chan K, McVary K, Schade D and the **DCCT/EDIC Research Group**. Prevalence and predictors of sexual dysfunction in men with type 1 diabetes enrolled in DCCT/EDIC. *Diabetes* 2005; 54 (suppl 1):A8.
128. Boright A, Paterson AD, Mirea L, Mowjoodi A, Poloumienko A, Bull SB, Scherer SW, Zinman B and the **DCCT/EDIC Research Group**. Genetic variation of apolipoprotein E (APOE) is associated with persistent microalbuminuria in type 1 diabetes. The DCCT/EDIC genetics study. *Diabetes* 2005; 54 (suppl 1):A207.
129. Penson D, Wessels H, Cleary P, Chan K, Rutledge B, McVary K, Schwartz S, Jacobson A, and the **DCCT/EDIC Research Group**. What aspects of sexual dysfunction are most bothersome to men with diabetes: results from DCCT/EDIC. *Diabetes* 2005; 54 (suppl 1): A219.

Diabetes Prevention Program (D.M. Nathan, Study Chairman)

130. **Diabetes Prevention Program Research Group**. The Diabetes Prevention Program (DPP). *Diabetes* 1997; 46 (suppl 1):138A.
131. **DPP Research Group**. Effects of changes in weight, diet and physical activity on risk of diabetes with intensive lifestyle intervention in the Diabetes Prevention Program. *Diabetes* 2002; 51 (suppl 2):A28.
132. **DPP Research Group**. The cost-effectiveness of DPP intervention to delay or prevent Type 2 diabetes. *Diabetes* 2002; 51 (suppl 2):A74.

133. **DPP Research Group.** The Diabetes Prevention Program (DPP): Screening approach and yield. *Diabetes* 2002; 51 (suppl 2):A224.
134. **DPP Research Group.** Behavioral factors associated with weight loss among lifestyle participants in the Diabetes Prevention Program (DPP). *Diabetes* 2002; 51 (suppl 2):A240.
135. **DPP Research Group.** Association of demographic, anthropometric, and metabolic factors with baseline cardiovascular disease (CVD) risk factors in the Diabetes Prevention Program. *Diabetes* 2003; 52 (suppl 1):A168.
136. **DPP Research Group.** Impact of lifestyle and metformin therapy on cardiovascular disease (CVD) risk factors and events in the Diabetes Prevention Program. *Diabetes* 2003; 52 (suppl 1):A169.
137. **DPP Research Group.** The effects of life-style intervention (ILS) and metformin (MET) on C-reactive protein (CRP), tissue plasminogen activator (TPA) and fibrinogen (FIB) in the Diabetes Prevention Program (DPP). *Diabetes* 2003; 52 (suppl 1):A18.
138. **DPP Research Group.** Depressive symptomatology among DPP participants: Level on entry and over time. *Diabetes* 2003; 52 (suppl 1):A38.
139. **DPP Research Group.** Prevention of Type 2 diabetes with troglitazone in the Diabetes Prevention Program (DPP). *Diabetes* 2003; 52 (suppl 1):A58.
140. **DPP Research Group.** Depressive symptomatology on entry to the Diabetes prevention Program is a weak predictor of progression to diabetes among participants in the intensive lifestyle arm. *Diabetes* 2003; 52 (suppl 1):A420.
141. **DPP Research Group.** Role of insulin secretion and sensitivity in predicting type 2 diabetes in the Diabetes Prevention Program (DPP). *Diabetes* 2003; 52 (suppl 1):A230.
142. **DPP Research Group.** Delay and prevention of type 2 diabetes: Computer modeling of the DPP. *Diabetes* 2004; 53 (suppl 2):A240.
143. **DPP Research Group.** The effect of metformin on liver function tests in the Diabetes Prevention Program. *Diabetes* 2004; 53 (suppl 2):A240.
144. **DPP Research Group.** Effects of glycemic status on CVD risk factors in the placebo group of the Diabetes Prevention Program. *Diabetes* 2004; 53 (suppl 2):A240.
145. **DPP Research Group.** Intensive lifestyle intervention reduces prevalence of urinary incontinence in the Diabetes Prevention Program (DPP). *Diabetes* 2004; 53 (suppl 2):A240.
146. **DPP Research Group.** Is fasting plasma glucose adequate for detecting the development of diabetes in individuals with impaired glucose tolerance? *Diabetes* 2004; 53 (suppl 2):A240.
147. **DPP Research Group.** The relation of baseline body fat and body fat distribution

- measured by computed tomography (CT) to the development of diabetes in the Diabetes prevention Program. *Diabetes* 2005; 53 (suppl 1):A245.
148. **DPP Research Group.** Autonomic nervous system dysfunction and incident diabetes. *Diabetes* 2005; 54 (suppl 1):A245.
 149. **DPP Research Group.** Insulin secretion, weight loss, and the risk of developing diabetes in participants treated with metformin vs placebo in the Diabetes Prevention Program (DPP). *Diabetes* 2005; 54 (suppl 1):A245.
 150. **DPP Research Group.** Exceptional effectiveness of lifestyle modification in older participants in the DPP. *Diabetes* 2005; 54 (suppl 1):A245.
 151. **DPP Research Group.** Changes in health utilities with changes in body weight in the DPP. *Diabetes* 2006; 55 (suppl 1): A209.
 152. **DPP Research Group.** Repeat glucose testing to confirm glucose tolerance status: Implications for diagnosing diabetes in high risk adults. *Diabetes* 2006; 55 (suppl 1): A209.
 153. **DPP Research Group.** The diabetes associated polymorphism PPARG P12A and KCNJ11 E23 K influence progression to type 2 diabetes and response to interventions in the Diabetes Prevention Program. *Diabetes* 2006; 55 (suppl 1): A209.
 154. **DPP Research Group.** Depression symptoms, antidepressant medicine use and risk of developing diabetes in Diabetes Prevention Program participants. *Diabetes* 2006; 55 (suppl 1): A210.

12/14/09